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Abstract        
Introduction 
Human immunodeficiency virus (HIV) has been associated with invasive enteric infections in 
HIV-infected patients, since it was first described in the 1980s.  In South Africa, HIV remains 
an important health challenge, despite the introduction of antiretroviral therapy (ART) in 
2003. In association with this, is an ongoing problem of invasive enteric infections, including 
those due to Shigella and Salmonella, including Salmonella enterica serovar Typhi 
(Salmonella Typhi). There are few South African data available as to the incidence of 
invasive disease due to these pathogens and how these data may contrast with the 
presentation and outcome in HIV-uninfected patients. The associated risk factors for 
mortality due to invasive enteric pathogens and whether there has been a response with ART 
as an intervention also needs further elucidation. 
Aims 
This work was undertaken to better describe the burden of invasive enteric infections 
(Shigella, nontyphoidal Salmonella and Salmonella Typhi) in association with HIV, define 
risk factors for mortality and establish whether the introduction of ART has impacted on 
disease burdens due to these pathogens. 
Methods 
Laboratory-based surveillance for enteric pathogens was initiated in 2003. Basic 
demographic details (age and gender) were collected on all patients where possible. In 25 
hospital sites in all nine provinces, additional clinical information was collected by trained 
surveillance officers, including HIV status, data reflecting severity of illness, other immune 
suppressive conditions, antimicrobial and antiretroviral usage and outcome (survival versus 
death). Laboratories were requested to transport all isolates to the Centre for Enteric Diseases 
(CED) at the National Institute for Communicable Diseases of the National Health 
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Laboratory Service (NHLS) in Johannesburg for further characterisation, including 
serotyping, antimicrobial susceptibility testing and molecular typing where relevant (whether 
isolates could respectively be classified as Salmonella Typhimurium ST313 and Salmonella 
Typhi H58). Additional cases were sought through audits of the Central Data Warehouse 
(CDW) of the NHLS. 
 
Annual incidence rates were calculated according to published estimates of population by age 
group by the Actuarial Society of South Africa for the Department of Statistics of the South 
African government. Analyses were specifically directed at invasive shigellosis, Salmonella 
meningitis, typhoid fever in South Africa and nontyphoidal salmonellosis in Gauteng 
Province, South Africa. Data were recorded in an Access database and analysed using chi-
squared test to establish differences between HIV-infected and uninfected individuals and 
univariate and multivariate analysis to compare risk factors for mortality. Data in the number 
of patients accessing ART were derived through audits of the CDW, by using the numbers of 
patients on whom viral loads were done annually as a proxy. 
 
Results 
Between 2003 and 2013, a total of 10111 invasive enteric isolates were received by CED. For 
patients for whom sex was recorded, 3283/6244 (52.6%) of patients presenting with invasive 
enteric infections were male; invasive disease was predominantly observed in children less 
than five years of age (1605/6131; 26.2%) and those who were aged between 25 and 54 years 
(3186/6131; 52.0%), with the exception of typhoid fever where the major burden was in 
patients aged 5 to 14 years (302/855; 35.3%). 
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More HIV-infected adult women were observed with invasive shigellosis (P=0.002) and with 
typhoid fever compared with adult men (P=0.009). Adults aged ≥ 15 years were more likely 
to die than children aged < 15 years (invasive shigellosis, odds ratio [OR]=3.2, 95% 
confidence interval [CI]=1.6 – 6.6, P=0.001; Salmonella meningitis, OR=3.7, 95% CI=1.7 – 
8.1, P=0.001; typhoid fever, OR=3.7, 95% CI=1.1 – 14.9, P=0.03; invasive nontyphoidal 
salmonellosis, OR=2.0, 95% CI=1.6 – 2.5, P<0.001). 
 
HIV-infected patients had a significantly higher risk of mortality compared with HIV-
uninfected patients (invasive shigellosis, OR=4.1, 95% CI=1.5 – 11.8, P=0.008; Salmonella 
meningitis OR=5.3, 95% CI=1.4-20.0, P=0.013; typhoid fever, OR=11.3, 95% CI=3.0 – 42.4, 
P<0.001; invasive nontyphoidal salmonellosis OR=2.5, 95% CI=1.7 – 3.5, P<0.001). In all 
patients, severity of illness was the most significant factor contributing to mortality (invasive 
shigellosis, OR=22.9, 95% CI=2.7 – 194.2, P=0.004; Salmonella meningitis OR=21.6, 95% 
CI=3.5 – 133.3, P=0.01; typhoid fever, OR=10.8, 95% CI=2.9 – 39.5, P<0.001; invasive 
nontyphoidal salmonellosis OR=5.4, 95% CI=3.6 – 8.1, P<0.001). Between 2003 and 2013, 
ART was significantly associated with decreasing incidence rates of invasive nontyphoidal 
salmonellosis in adults aged 25 - 49 years (R=-0.92; P<0.001), but not in children (R=-0.50; 
P=0.14). 
Conclusion              
Decreasing incidence rates of invasive nontyphoidal salmonellosis and shigellosis suggest 
that ART is having an impact on opportunistic enteric disease in HIV. Further work is 
necessary however, to fully understand the associations between age, sex and invasive enteric 
pathogens. Specifically, this work would include typhoid fever, Shigella transmission from 
child to adult carer, development of invasive enteric infections in HIV-exposed children and 
whether the decreasing incidence rates can be sustained. Moving forward, an understanding 
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of invasive enteric infections in the HIV-uninfected patient may assist in targeting severity of 
illness as a risk factor for mortality.  
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Prologue 
The original desire to study medicine came through a number of influences, most significant 
of these being  my father, who as a medical physicist, had spurred my interest and as the 
father of daughters, believed a woman, in those days could function well in what was a 
predominantly male profession. In addition, I had a younger sister who developed an 
osteosarcoma at the age of 8 years. Although she survived, her right arm was amputated and 
she received long courses of radiotherapy and chemotherapy as part of her treatment. She was 
finally declared cancer-free after 30 years. My intention, at the innocent age of 15 years, was 
therefore to study medicine so that I could become a paediatric oncologist, and through 
medical research, find new, better and less traumatic ways of treating children with cancer. 
 
I enrolled as a medical student at the University of the Witwatersrand (Wits) in 1981, but 
discovered that the early, preclinical years, were a little dry and although the workload was 
tremendous, much of the work, particularly in the second year of anatomy, involved large 
quantities of rote learning and less of analytical thinking. This was somewhat against my 
nature and I broke away from the traditional medical path for a year to study and earn 
additional degree of BSc (Med), giving me my first taste of scientific research. It was an 
extremely stimulating and constructive time and through exposure to some extraordinary 
scientists, including Prof Philip Tobias in the Department of Anatomy and Prof Ann Andrews 
in Microanatomy, I learnt much about experimental rigour and critical review of scientific 
studies. Another lecturer, who became the first to try to teach me biostatistics, was Prof Allen 
in the Department of Anatomy – little did I realise how important these lectures were then!  
 
I joined the staff of Sizwe (then Rietfontein) Hospital as a medical officer in 1990. The 
exposure to infectious disease and an extraordinarily stimulating year of gaining my DTM&H 
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while I was working at Rietfontein in 1991 had enthused me to study medical microbiology. 
The Head of Department and person who had the final say in my appointment as a 
microbiology registrar, was Professor Keith Klugman. It was the start of a long and extremely 
(for myself at least) productive association with one of my current PhD supervisors. 
 
I was fortunate to spend three months as a guest researcher in the Foodborne Diseases Branch 
at the Centers for Disease Control and Prevention in Atlanta, USA, in 1997, following my 
graduation as a Medical Microbiologist. At the CDC, I was given my first introduction on the 
importance of setting up a reference laboratory, at a time when molecular diagnostics and 
epidemiological techniques were just being introduced at the highest levels and had not yet 
become the norm. Although I was primarily laboratory-based, I had interaction with the 
epidemiologists while there as well, and met Dr Fred Angulo, a senior epidemiologist in the 
food-borne diseases branch at the time; later he was to become the second supervisor on my 
PhD. 
 
It took another 10 years or more, before I was ready to embark on my PhD. In the intervening 
years, my supervisor and mentor from my Masters years, Keith Klugman, had emigrated to 
the USA. I had been invited to Geneva a few years earlier, to sit on a WHO expert committee 
to describe the global burden of foodborne diseases, and was introduced to a group of 
passionate and dedicated scientists with a deep and sincere concern in gathering well-
researched, relevant and accurate data for this project. Here, I again met with Fred Angulo, 
one of the major forces involved in the project. Sitting at a dinner table that year, I was 
chatting with an Australian colleague who had just embarked on his PhD; I discussed my 
desire to do a PhD with him: he suggested that Fred would “see me through”. 
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Shortly after my return from that meeting, I met with Keith, who was visiting South Africa. 
In discussions with him, he pointed out that he had been supervising a colleague of mine who 
was just finishing her PhD, and asked if I was ready to embark on the same. I replied: 
“Funny, Keith, I was just about to ask you about that…” 
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1. Review of the literature 
1.1. HIV, opportunistic infections and the introduction of 
antiretroviral therapy 
 
Globally, HIV remains a severe problem and South Africa has one of the highest rates of HIV 
infection in the world, different sources estimating that between 5.2 and 5.7 million people 
are infected (1-3). There has been major impact on life expectancy, with a major negative 
effect on the economically active sector of the population, due to morbidity and mortality in 
this age group (1;4;5). The infant mortality rate in South Africa, which previously could be 
partially ascribed to HIV, was one of the highest in the world in 2005 and had increased since 
the millennium (6), but has decreased substantially since (7;8). Nonetheless, HIV uninfected 
infants who were HIV exposed in utero or at birth remain at risk for a number of infectious 
diseases (9).  Highly active antiretroviral therapy (HAART) was introduced in South Africa 
in 2004 (10),  and has been phased in over a number of years, the coverage being estimated at 
40.2% for those with CD4+ less than 200 cells per µl of blood or World Health Organization 
stage 4 criteria (11). However, following the current South African HIV Clinicians Society 
guidelines,  coverage is only 22.2% (11) and may thus be deemed inadequate to prevent 
opportunistic infection. 
 
The full impact on the introduction of HAART in South Africa is not completely elucidated: 
the role that it has played in morbidity and mortality due to opportunistic and acute bacterial 
infections is only partially described. If we accept that coverage with HAART may be 
inadequate, it becomes more critical to measure the effects of acute bacterial opportunistic 
infections on disease (11). 
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It is well recognised that HIV co-infection is a high risk factor for both common human 
pathogens as well as opportunistic pathogens and this remains relevant, even in the era of 
HAART (12). African studies have shown that this includes, amongst others, acute bacterial 
infections, co-infections with other opportunistic pathogens and chronic infections including 
cryptococcosis, tuberculosis and Pneumocystis pneumonia (13). The association of these last 
three pathogens with HIV is well-elucidated, but that of the acute invasive bacterial 
pathogens, including the enteric bacteria, is less easily described, due to the occurrence of 
these in association with other clinical conditions in Africa, as well as the occurrence in 
healthy individuals (13-23). 
 
1.2 The enteric bacteria and the association with acute invasive 
disease 
 
Enteric pathogens are important causes of morbidity and mortality in the developing world 
(24;25) and may be associated with serious consequences in these patients. Among the most 
common of the pathogenic enteric bacteria are non-typhoidal Salmonella, Shigella and 
Campylobacter, all of which had been described as associated with HIV (26-29), including 
other immune suppressed or immune deficient states (14-18;20;21;30;31). 
 
Although not included in this work, Campylobacter has a strong history of causing invasive 
infections in the presence of HIV. As one of the most ubiquitous of the pathogenic enteric 
bacteria (32-34), the association of Campylobacter diarrhoea with HIV, particularly in men 
who have sex with men (MSM), is not unexpected (35-37). In addition, Campylobacter 
bacteraemia may occur both in HIV-infected individuals as well as other comorbidities, but 
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appears rare with a prevalence of 0.004 per cent compared with the numbers of reported 
diarrhoea cases in Denmark (37). 
 
Conversely, Shigella and Salmonella share a common ancestry, and are similar in that both 
pathogens invade the intestinal mucosa, causing mucosal damage, diarrhoea and dysentery 
(38). The breaching of the mucosal barrier potentially conveys an advantage, compared with 
other intestinal pathogens, in causing systemic disease; this may well be potentiated in the 
immune suppressed patient. Previously, meta-analysis has described both of these pathogens 
as causes of community-acquired bacteraemias in Africa (23).  
 
In Africa, shigellae are recognised as one of the commonest causes of diarrhoeal morbidity 
and mortality in all age groups (24;25;39). Invasive shigellosis was recognised as an unusual, 
but important manifestation of disease in HIV, early in the course of the HIV epidemic, with 
reports emanating from the developed world (40-43), but has also been associated with 
malnutrition in children (44;45). Shigella have also been associated with invasive disease in 
HIV-infected patients in South Africa (46), but the full impact of the disease in South Africa, 
where major health disparities exist, is poorly understood. The epidemiology of invasive 
shigellosis in association with HIV in South Africa differs from that previously described: as 
a pathogen of MSM (47); given the differing epidemiology of HIV, which is typically due to 
heterosexual transmission in South Africa (2;48), and was previously described in young 
children in association with HIV and malnutrition (49). Recommendations addressing the risk 
factors may decrease morbidity and mortality in systemic disease, as well as decreasing the 
incidence rates in gastroenteritis in these patients (27;44;50) given the ubiquitous nature of 
this pathogen.  
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Typically, common acute infectious diseases, such as invasive pneumococcal disease, present 
more commonly in HIV-infected patients (51;52) in a setting where HIV infection is 
common. Typhoid fever, due to Salmonella enterica serovar Typhi, remains an important 
public health problem (53;54). The association between typhoid fever and HIV is also not 
fully elucidated, and even confusing, and there are limited reports in the literature regarding 
the association of Salmonella Typhi with HIV (55-57). Gotuzzo et al found that HIV-infected 
patients had a 60-fold increased likelihood of developing typhoid fever when compared with 
the general population in Lima, Peru (55), but few researchers have been able to confirm this. 
Conversely, Crump et al have recently shown that HIV appears protective against typhoid 
fever in northern Tanzania, although the reasons for this are not well understood (13), and 
confirmed observations of a meta-analysis of causes of bacteraemia in Africa (23): further 
work may better clarify the association, which appears to be based primarily on fever studies 
(recorded temperature in a patient >38°C) . Antimicrobial resistance appears to be increasing 
in this pathogen in South Africa (58-65), with the emergence of quinolone resistance a major 
cause for concern (66). It is apparent that in HIV-infected individuals, currently available 
typhoid vaccines are associated with a poor immune response (67). A better understanding of 
the role of HIV in typhoid fever would assist in preparation of vaccine guidelines in these 
patients, antimicrobial management and an appropriate public health approach. Of further 
concern is the spread of the virulent haplotype, Salmonella Typhi H58, which is frequently 
associated with multi-drug resistance, from South East Asia to Africa and the potential 
impact this may have on an already vulnerable, immune-suppressed population (68;69).  
 
The role of invasive nontyphoidal salmonellosis as an opportunistic infection in HIV-infected 
patients has been well studied elsewhere (70-74), but aspects of this disease remain poorly 
understood. The importance of this problem in Africa is well recognised, and resulted in a 
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consortium being formed, to better understand the role, impact and potential interventions for 
this disease in Africa (74;75). The impact of HIV on Salmonella meningitis (76-79), 
including a high mortality in HIV-infected infants in some studies (79), conflicting with the 
results of others (76), may be due to different management protocols. The role of co-infection 
due to other pathogens or co-morbidity, the potential association of meningitis with certain 
serovars, the impact of multidrug resistance on outcome remains to be elucidated and the 
relevance of unusual serovars, particularly in a nosocomial setting, needs to be elucidated. 
Given the morbidity and mortality associated with meningitis, a better understanding of these 
associations may advance patient management and decrease mortality (77;78). 
 
Changing incidence rates of invasive nontyphoidal salmonellosis since the introduction of 
HAART into South Africa in 2004 (2), have not been  examined.  A defective immune 
response in HIV-infected adults appears central to progression to invasive disease due to 
Salmonella, as a result of both abnormal cell mediated and humoral immunity (80;81). 
Invasive disease in HIV-uninfected patients has not been extensively researched in South 
Africa and there may be aspects that differentiate this from disease in HIV-infected patients 
(20;76;82-84). The importance of non-invasive Salmonella as a common cause of diarrhoea 
globally has been recently described and the organism is responsible for 93.8 million cases 
and 155 000 deaths (76;85). It is likely, given the prevalence of this pathogen, that even in the 
HIV-uninfected patient, invasive disease may play a role in South Africa: invasive disease 
has been described at the extremes of age or in association with other immunosuppressive 
conditions (20;82;83;86;87). The nosocomial nature of Salmonella infections in South Africa 
has been previously described, with devastating effects on hospitalised patients (72;83) and 
adding to the current health care burden. Unpublished evidence suggests that there may be an 
association with invasive disease due to non-typhoidal Salmonella in HIV- infected patients, 
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which may affect homes and communities. These organisms appear to be multidrug resistant 
(72;83;88) and an unusual serovar, Salmonella enterica serovar Isangi (Salmonella Isangi) 
appears an uncommon cause of disease beyond Africa (83;88-92). 
 
1.2. Pathogenesis of shigellosis and salmonellosis 
Enteric infections remain common in both children and adults in the developing world, an 
estimated 1.7 billion episodes occurring in children under five years of age in low to middle 
income countries (93) and two billion cases occurring overall in 2010 (94). Against this 
background, certain factors must nonetheless be in place for the organism to cause invasive 
disease, both host- and pathogen- specific. Both Shigella and Salmonella are able to invade 
the gut epithelium to cause diarrhoea, but only Salmonella Typhi and Paratyphi (including 
Salmonella Paratyphi A, Salmonella Paratyphi B and Salmonella Paratyphi C) are typically 
able to cause systemic disease, due to specific adaptations to overcome the human host’s 
immune system in the immune-competent host. 
 
1.2.1. Shigella and the host response 
The pathogenesis of Shigella diarrhoea has been the subject of many studies and there are 
some excellent reviews. Shigella have a very small infectious dose and are easily transmitted 
through person-to-person spread, by flies and via environmental contamination, being 
specifically associated with poor sanitation and hygiene (95;96). The organisms gain entry in 
the epithelial cells of the large intestine, utilising a type III secretion system, (T3SS), 
preferentially via the M cells (microfold cells) through macropinocytosis (figure 1) (97;98). 
From the M cells, they are passed by transcytosis to resident macrophages, but evade 
intracellular killing by inducing apoptosis (99). Shigellae have thus evolved to utilise the 
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primary defence to subvert the resultant inflammatory process, such that the intestinal tissue 
is destabilised. This permits invasion of the gut epithelial cells from the basolateral aspect: on 
contact with the epithelial cell, T3SS effector proteins trigger bacterial uptake within 
vacuoles, but the vacuolar membrane is disrupted by the pathogen and the organisms multiply 
within the cytoplasm (97). Shigellae induce actin polymerisation in the epithelial cells at one 
pole, providing the propulsive force to move within and between cells (figure 1) (97;99). 
Massive and rapid colonization of the epithelial cells is followed by reprogramming of these 
cells to preferentially express interleukin-8 (IL-8), recruiting polymorphonuclear cells (98), 
with extensive epithelial cell destruction (100).  
 
By inducing apoptosis in macrophages, the shigellae also subvert the acute inflammatory 
response through the T3SS effectors in the Peyer’s patches of the gut (101). There is 
recruitment of T-cells (101), with specific targeting of CD4+ Th17 cells by Shigella (102), 
the priming of which conferring only limited protection against reinfection (102).  Shigellae 
invade B cells, which undergo apoptosis (103), there is impairment of dendritic cells 
recruitment (104)  and CD8+  T-cells fail to respond to infection (105). 
 
Studies on S. sonnei have shown that the O antigen (OAg) lipopolysaccharide capsule, absent 
from S. flexneri 2a, which assists S. sonnei to resist complement-mediated killing. In contrast, 
experimental knockout of the capsule increased invasiveness in rabbit gut epithelial cells, 
increasing the inflammatory response and reducing spread to peripheral organs through 
enhanced complement-mediated killing (106). Goh et al have confirmed a role for 
complement-mediated protection against invasive nontyphoidal salmonellosis in HIV-
uninfected Africans, but in HIV-infected Africans, Immunoglobulin A (IgA) and IgG2 have 
poor ability to activate complement (107;108). Similar factors may be at play in invasive 
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shigellosis, and Shigella may cause bacteraemias in immune suppressed patients; however, 
immunity to different  Shigella  serotypes may be cross-protective (109). Lower case 
numbers of invasive Shigella would thus occur, whereas invasive Salmonella and the 
presence of non-specific antibodies (discussed below) (110), may contribute to a greater 
burden of invasive disease. 
 
Specifically therefore, Shigella has adapted to causing disease in the presence of a number of 
factors, through the subversion of host immunity via the T3SS and molecular cross-talk: 
impaired host immunity and immunologic cross-protection may be disadvantageous in 
association with invasion and systemic shigellosis in HIV. The development of invasive 
shigellosis is a rarer event compared with the occurrence of invasive non-typhoidal 
Salmonella in HIV-infected individuals (111;112).  
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Figure 1. Pathogenesis of Shigella infection and the immune response. 
Intracellular survival and basolateral invasion allow Shigella to penetrate the gut epithelium, adapted from Ashida et al (97).
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1.2.2. Salmonella and the host response 
Salmonella enterica has a similar ability to invade the gut as Shigella species – and also 
employs a type III secretion system (figure 2). Non-typhoidal Salmonella have evolved 
differently from the typhoidal group, and show a range of host adaptation: some are highly 
host-adapted, similar to Salmonella Typhi, with the ability to invade the animal host, whereas 
others are “generalists” and typically cause enteric disease in the immune-competent 
individual (113). 
 
The non-typhoidal Salmonella (NTS) have less ability to invade the human host, although 
certain serovars have a higher invasiveness potential than others, including Salmonella 
Dublin and Salmonella Choleraesuis (114). Irrespective, the major pathogen that has emerged 
in Africa as a cause of invasive nontyphoidal salmonellosis, is Salmonella Typhimurium 
(115;116), in association with the HIV epidemic on the continent (112;113). 
 
The pathogenesis of NTS diarrhoea is dependent on the presence of pathogenicity islands, 
acquired through the horizontal transfer of genes, and located either chromosomally or on the 
bacterial genome (117). They function to both promote host invasion, intracellular survival 
and to induce host immunity (Table 1) (117). Once ingested, these pathogens successfully 
compete with the gut microbiota, multiplying through the preferential utilisation of nutrients, 
at a cost to competing pathogens  (118). Salmonella invade both non-phagocytic (119) and 
preferentially, the phagocytic microfold (M)-cells (120) of the intestinal epithelium. Within 
the gut epithelial cells, the organisms exist with membrane-bound Salmonella-containing 
vacuoles (SCV), distinct from the phagosome (117), avoiding killing by preventing lysosome 
fusion (120) (Figure 2).  Salmonellae can survive and replicate within the SCV, through the 
production of various effector proteins enabling the pathogen to translocate into the host 
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cytoplasm leading to rearrangements of the actin cytoskeleton (117;118). Salmonellae invade 
basolaterally through the epithelial lining, reaching the Peyer’s patches, stimulating an 
immune response (117;118;120;121). Proinflammatory cytokines including interleukin (IL)-
1β, IL-6, interferon (IFN)-γ and tumour necrosis factor (TNF)-α are secreted, promoting 
systemic inflammation (117;118;121). Both CD4+ and CD8+ T-cells are important for 
protective immunity (121;122), although protective immunity requires the presence of 
functional B-cells (110;123). Bloodstream invasion by NTS in immune-suppressed 
individuals therefore results from three primary defects: loss of IL-17 producing CD4+ T-
cells, attenuation and dysregulation of cytokine production (118;121) and humoral defects in 
pathogen-specific IgG, due to B-cell defects (110;123) in HIV-infected individuals, 
associated with reduced IgG specific to  Salmonella lipopolysaccharide (124). 
 
As stated above, certain NTS appear to have a greater ability to invade (invasiveness index) 
than others, calculated by comparing the number of non-invasive to invasive cases (114). In 
association with the HIV epidemic, Salmonella Typhimurium has evolved to take advantage 
of the disease in Africa, with the emergence of Salmonella Typhimurium ST313 (115;116). 
The pathogen has become so common it has replaced Streptococcus pneumoniae as the most 
frequent cause of bacteraemia in parts of sub-Saharan Africa (125;126). Whole genome 
sequencing analysis of representative isolates from a number of African countries suggests it 
emerged temporally in close association with the HIV pandemic (116). However, recent 
evidence has also indicated that Salmonella Typhimurium ST313 has retained its ability to 
cause intestinal inflammation in both mice and macaque monkeys, highlighting the role of 
defective immunity, over intrinsic pathogen virulence, in its role in iNTS in Africa (127). 
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Table 1. Functions of major Salmonella pathogenicity islands (SPI). 
Pathogenicity Island 
Approximate 
size 
(kilobases) 
Type secretion 
system 
Features/Functions 
SPI-1 40 
Type III 
secretion system 
(T3SS) 
Invasion of intestinal epithelium; 
rearrangement of actin 
cytoskeleton; membrane 
ruffling; induction of interleukin-
8  
SPI-2 40 
Type III 
secretion system 
(T3SS) 
Intracellular survival in 
phagocytic cells; inhibition of 
phagosome-lysosome fusion; 
avoidance of intracellular killing;  
SPI-3 17  Intramacrophage survival 
SPI-4 27 
Type I secretion 
system (T1SS) 
Mediation of epithelial cell 
adhesion; role in oral virulence 
SPI-5 8  
Encodes virulence protein 
secreted by T3SS 
SPI-1 through  SPI-5 are common among Salmonella serovars, adapted from Hurley et al 
(117). 
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Molecular analysis suggests that it has emerged through partial selective genome degradation 
and the acquisition of pseudogenes, comparable to the emergence of Salmonella Typhi as a 
human pathogen (115). Salmonella Typhimurium ST313 shares a root with Salmonella 
Typhimurium ST19 (115), which is common in Europe and associated with diarrhoea in 
humans (115;128). Interestingly, the former stimulates less inflammasome activation 
(129;130), a feature typically associated with the invasive, human adapted serovars of 
Salmonella Typhi and Salmonella Paratyphi (131). This information has highlighted why 
invasive Salmonella Typhimurium has been associated with human-to-human, rather than 
zoonotic spread (132), including association with nosocomial bacteraemia in South Africa 
(88). In contrast, Salmonella Typhimurium ST19 has been associated with a nosocomial 
diarrhoeal outbreak in this country, but was rarely invasive, although the outbreak occurred in 
a vulnerable population (133). The ability of certain Salmonella Typhimurium strains to 
cause invasive disease, whereas others appear to cause diarrhoea only, even in severely 
immune suppressed HIV-infected patients, has also been documented in the developed world 
(134).  
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Figure 2. Pathogenesis of Salmonella infection and the immune response. 
This diagram indicates key defects contributing to the development of invasive non-typhoidal Salmonella disease in HIV (113;117); adapted 
from Hurley et al (117).
1. Loss of interleukin 17-producing CD4 T cells in HIV results in 
failure to maintain the epithelial cell barrier with additional loss 
of antimicrobial peptides, failure of neutrophil recruitment and 
translocation and invasion of salmonellae. 
3. Attenuation of proinflammatory 
responses and dysregulation of 
cytokine production results in 
intracellular persistence of 
salmonellae and recrudescence of 
bacteraemia. 
2.  Humoral defects in Serum IgG 
against Salmonella lipopolysaccharide 
inhibits effective serum killing of 
salmonellae. 
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Similarly to the non-typhoidal serovars, Salmonella Typhi has evolved over the past 30 000 
(135) years to bypass the gut immune system through the acquisition of a number of 
virulence factors, permitting it to survive in human macrophages. The core genome is 
approximately 90% common including the primary pathogenicity islands 1 – 5, but there are 
a further 300 to 400 genes that are associated with specific phages or SPIs (136). Differences 
thus emerge in the failure of this pathogen to elicit a high inflammatory response in healthy 
individuals during the primary invasion (137). Salmonella Typhi invades via the small 
intestine (137), but in contrast to NTS, there is minimal neutrophil recruitment (136). Failure 
to elicit the marked inflammatory response observed with other enteric pathogens may be due 
to innate characteristics of Salmonella Typhi, which is associated with elevated pyrogenic 
cytokines, including TNF- α and IL1-β, through expression of various virulence mechanisms 
(138). In contrast, macrophage-like cells infected with Salmonella Typhi have reduced 
expression of IL-8 (138), the neutrophil chemoattractant which is additionally induced by 
bacterial flagellin. Salmonella Typhi then gain access to the underlying lymphoid tissues, 
where they are taken up by macrophages and possibly phagocytosed by dendritic cells, in 
which they replicate (136). Infection then spreads via the mesenteric lymph nodes through the 
common bile duct to the blood stream, resulting in a primary bacteraemia (136;137). 
Salmonellae are taken up by phagocytic cells of the reticuloendothelial system (liver, spleen 
and bone marrow); seeding of bacteria from here causes the secondary bacteraemia 
(136;137). 
 
Over the past 30 years, Salmonella Typhi H58 has emerged to dominate in Asia and Africa, 
at a well-described cost to antimicrobial-susceptible strains (139). In contrast to the HIV-
associated emergence of multidrug resistant Salmonella Typhimurium ST313 (116), which 
appears rather to be the result of widespread use of broad-spectrum antimicrobials for the 
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treatment of typhoid fever (68), in combination with enhanced fitness associated with 
multidrug resistance and the fluoroquinolones in particular (140). 
1.4 Public health implications of invasive enteric pathogens 
associated with HIV-infection 
The Global Burden of Disease study, updated in 2013, was undertaken in order to identify 
public health priorities for potential policy development and interventions at global, regional 
and country levels for all major causes of morbidity and premature mortality (141;142).  In 
tandem with these efforts, systematic reviews examining the burden of food and waterborne 
pathogens were undertaken (85;94). Despite focussed attempts in these studies to address the 
association of invasive enteric pathogens, and particularly invasive NTS, in Africa, major 
data gaps have remained (112).  
 
Recently, concerted efforts have been made to identify these gaps at a special meeting, 
convened to address a selection of these in Blantyre, Malawi, on 18 and 19 November 2014 
(143). A comprehensive collection of publications that reviewed disease incidence due to 
iNTS in a number of African countries confirmed that burden of disease is decreasing in a 
number of African countries. Muthumbi et al confirmed a decrease in incidence rates from 50 
cases per 100 000 person-years of observation (PYO) to 10 cases per 100 000 PYO, in 
children aged < 15 years in Kilifi, Kenya, over a 15 year period but ascribed this reduction 
primarily to reduced rates of malaria (144). They did not however note a similar decrease in 
adults over time, in whom iNTS disease was primarily associated with HIV: in HIV-infected 
patients the incidence was 13.2 per 100 000 PYO (144). Similarly, a decrease in iNTS disease 
in Mozambican children in Manhiça province, from 200 to 25 per 100 000 between 2001 and 
2014 was primarily ascribed to malaria control, although malnutrition remained a major risk 
factor (145). Feasey et al have previously shown that a multipronged approach, including 
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improving nutritional status, controlling malaria and management of HIV contributed to 
decreasing iNTS incidence in Malawian children in Blantyre by ~12% per annum between 
2001 and 2010 (146). While fewer reports specifically examine iNTS in adults, undoubtedly 
controlling HIV has had an impact on the number of blood stream infections as well as the 
case fatality rates (CFR): culture-confirmed bacteraemias decreased from 16% to 10% of 
suspected cases and CFR fell from 40% to 14% from 1997 to 2010 in Malawi (147). Where 
antiretroviral therapy is less accessible, cases numbers have remained constant: in adults aged 
≥15 years in Kilifi, Kenya, case rates have remained unchanged at 1.7 per100 000 person 
years (144). Conversely to older, popular conceptions, the role of humans as reservoirs for 
the transmission of NTS in Africa has emerged as critical in maintaining disease in HIV-
infected populations and Salmonella Typhimurium ST313 in particular has become adapted 
as a human pathogen, through lineage-specific genome degradation, with some similarities to 
those observed in Salmonella Typhi (148). 
 
Salmonella Typhi remains an important cause of morbidity and mortality in Africa and 
burden of disease calculations have suggested that it is common in Africa (149), although 
South African estimates used in this study were taken from surveillance conducted around a 
vaccine trial in the 1980s (150). Updated burden estimates are required to better understand 
the role of water and sanitation programmes in current incidence rates, as well as the role of 
the emerging multidrug resistant haplotype, Salmonella Typhi H58 (139), in disease 
causation among HIV-infected and uninfected patients in South Africa. 
 
Data regarding systemic shigellosis are less complete. A limited case series describing 
invasive shigellosis reported from Chris Hani-Baragwanath Hospital in Johannesburg, South 
Africa, described all adult patients as HIV-infected, compared with 30% of children (46). 
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Reddy et al undertook a systematic review and calculated that <1% of bacteraemias in Africa 
are due to invasive Shigella (23), but did not comment on the association with HIV. 
Nonetheless, the burden of shigellosis in developing countries is high and causes an estimated 
4% of cases in children aged from 12 – 24 months (151). As rates of person-to-person 
transmission are estimated as being responsible for ~50% of cases (152), risk factors for 
acquiring disease in HIV-infected adults would be expected to be proportionately high. At the 
same time, however, there is a major impetus to develop vaccines for Shigella: the 
predominance of  S. sonnei, S. flexneri 2a, S. flexneri 3a, and S. flexneri 6 means a vaccine 
against these strains would protect against ~90% of Shigella infections, should a vaccine be 
developed (153). Despite this, additional public health considerations, including provision of 
potable water and adequate sanitation should not be ignored in control of disease (109). 
 
The burden of invasive enteric infections has hence taken a massive social and financial toll 
in South Africa. Socially, due to HIV deaths in South Africa, there were an estimated 
122 000 children living in 60 000 child-only households in 2006, representing 0.67% of 
children in South Africa (154). To further complicate matters, misclassifications of HIV-
related deaths on death certificates (excluding HIV as a cause of death) suggests an excessive 
mortality due to food-borne disease salmonellosis (155). The introduction of ART should 
impact on invasive enteric infections: in total, the programme will have averted 900 000 
orphans in South Africa by 2020 (156), should it be successful. More recently, new evidence 
has suggested that there is a serious lag in the numbers of adult men accessing ART, 
compared with the numbers of women: between 2003 and 2011, the ratio between HIV-
related mortality in adult women (≥15 years of age) compared with adult men in Hlabisa, in 
rural Kwazulu-Natal, South Africa, declined significantly from 0.93 to 0.73 (P=0.046) (157). 
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Inpatient treatment costs for invasive enteric infections in association with HIV cannot be 
calculated in the absence of burden information. Long et al, however, recently calculated that 
at a large Johannesburg hospital in 2010, acute invasive bacterial infections accounted for 
12% of all admissions, the majority (65%) being in HIV-infected patients (158). The cost of 
management per patient for an in-hospital stay, averaging 9 to 10 days, was estimated at 
~USD1800, or USD180 to USD 200 per day (158). Critically, in this series, none of the 
patients received any antiretroviral therapy although all were purportedly on an ART 
programmes, implying that they either continued on their own ART or that their treatment 
was disrupted (158). A previous study, at another Johannesburg hospital in 2005 found 
similar costs: in-patient care for HIV-infected patients for  a period of 8 to 9 days cost 
USD1114 – most patients were not receiving ART (159); ten years previously, prior to the 
introduction of ART, in-patient costs for HIV-infected patients were estimated at USD1175 
(160). Little improvement has occurred therefore over 20 years, in the costs of managing 
opportunistic pathogens in HIV-infected patients. 
 
In order to optimise management, it has become necessary to better define prevalence of 
HIV-associated opportunistic infections, including those due to the enteric pathogens. Due to 
its public health significance, the interaction of Salmonella Typhi with HIV needs to be better 
defined, to assess the potential of this pathogen to add to the burden of typhoid fever and 
whether this may change in a post-HIV era. Data on the actual disease incidence, as well as 
response to ART over an extended period, will define the success of antiretroviral treatment 
campaigns as well as provide guidance for policy makers and health economists to motivate 
for funds for disease management. Additionally, such information can provide baseline 
estimates for numbers of patients presenting with invasive enteric pathogens in a post-HIV 
era. Burgeoning antimicrobial resistance has additionally accelerated the need for effective 
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vaccines against Shigella and non-typhoidal Salmonella and improved vaccines for 
Salmonella Typhi. 
 
In 2013, a passionate plea was made regarding the proposed decrease in the funds provided 
by the President’s Emergency Plan for Aids Relief (PEPFAR) (161), which provided a large 
proportion of the funds for this project (see section 3.5 below). One of the arguments 
provided was how PEPFAR had done more for health in Africa than simply provide a 
channel for ART (162). This work additionally provides data that tests and confirms the 
validity of this statement, as it tells a story of an evolving laboratory-based surveillance 
network, which has provided extensive data on enteric pathogens in South Africa for public 
health action, beyond simply the association with HIV. 
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2. Aims 
This thesis aims to define the relationship of HIV and invasive disease due to enteric 
pathogens in South Africa (Figure 3): 
 
• To define the burden of invasive shigellosis in HIV-infected patients: Elaborate on the 
clinical and microbiological aspects of systemic shigellosis in a South African 
population and the relationship to HIV, including clinical outcome, age and sex 
related differences and relevance of different serotypes, from 2003 to 2009, using 
quantitative analysis; 
• To describe the association between HIV and meningitis due to non-typhoidal 
Salmonella: Investigate the impact of HIV on Salmonella meningitis in South African 
patients, and whether the outcome is affected by age or sex; to elaborate on the 
distribution of Salmonella serovars and antimicrobial resistance associated with 
Salmonella meningitis, the impact of the microbiological features on outcome 
including the presence of Salmonella Typhimurium ST313, from 2003 to 2013, using 
quantitative analytical techniques; 
• To examine the association of typhoid fever with HIV: review the role of HIV in the 
presentation, clinical course and outcome of typhoid fever in South Africa from 2003 
to 2013, using quantitative analysis and describe whether multidrug resistance and 
Salmonella Typhi haplotype H58 has a role in typhoid fever in South Africa and relate 
these findings to age and sex distribution in HIV-infected and HIV-uninfected 
patients; 
• To measure the impact of antiretroviral treatment (ART) programmes on invasive 
nontyphoidal salmonellosis (NTS) in HIV-infected patients: elucidate the role of ART 
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in relation to invasive NTS from 2003 to 2013, and establish whether this has 
impacted on incidence rates and outcome of invasive NTS in South Africa;   
• To compare these data with those from HIV-uninfected patients over the same time 
period, from 2003 to 2013, using quantitative analysis; and discover whether clinical 
and microbiological characteristics of isolates from these patients potentially play a 
role in disease presentation and outcome. 
These analyses are presented as a series of five papers (Appendix I). 
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     Figure 3. Conceptual framework developing analysis protocols for thesis.  
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3. Methods 
We conducted active laboratory-based surveillance for invasive cases of Shigella and 
Salmonella enterica, including Salmonella enterica serovar Typhi (Salmonella Typhi) in 
South Africa between 2003 and 2013. For completeness of results here additional analyses 
for invasive shigellosis from 2003 – 2013 are included. An invasive case was defined as the 
isolation of one of the afore-mentioned pathogens from a normally sterile body site. All 
clinical laboratories (both National Health Laboratory Service [NHLS] and private pathology 
laboratories) were requested to submit isolates to the Centre for Enteric Diseases (CED), 
National Institute for Communicable Diseases, for further characterisation, including 
biochemical confirmation of identity, antimicrobial susceptibility testing and limited 
molecular characterisation. In addition, we conducted audits for these pathogens of the NHLS 
laboratories through the Central Data Warehouse (CDW) of the NHLS, a repository for all 
pathology tests done at the NHLS (163), and conducted training during regular site visits to 
laboratories submitting isolates for surveillance (Figure 4). 
 
 
Figure 4. Site visit to Upington laboratory, Northern Cape, 2007. 
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3.1. Enhanced surveillance sites 
In addition, at selected sites around South Africa, we conducted enhanced sentinel 
surveillance for additional clinical information on these pathogens. These sites were selected 
to represent the population of South Africa as widely as possible (Figure 5). 
 
 
Figure 5. Sentinel surveillance sites selected for additional clinical data collection, South 
Africa, 2003 - 2013. 
These include Polokwane (Limpopo Province), Nelspruit (Mpumalanga Province), Pretoria 
and Johannesburg (Gauteng Province), Rustenburg and Klerksdorp (North West Province), 
Bloemfontein (Free State Province), Durban and Pietermaritzburg (Kwazulu-Natal Province), 
Kimberley (Northern Cape Province), Mthatha (Eastern Cape Province) and Cape Town 
(Western Cape Province). These sites were additionally selected on the basis of the hospital 
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laboratories being able to perform microbiology, as well as basic haematological and 
biochemical analysis of patients’ specimens. Tertiary care facilities and teaching hospitals 
were preferentially included as these would provide additional support for the surveillance 
programme. 
Trained surveillance officers identified relevant cases based on the isolation of Shigella or 
Salmonella from a normally sterile body site (e.g. cerebrospinal fluid, blood culture, plural 
fluid, synovial fluid) at each of these sites and interviewed patients based on standardised 
questionnaires, to capture information on age; sex; HIV status and risk factors for infection, 
including other immune compromising conditions and access to antiretroviral therapy (ART). 
Severity of illness (either Pitt bacteraemia score [PBS] (Table 2) (164) or Glasgow Coma 
Scale [GCS] where relevant), current and past antimicrobial exposure; CD4+ lymphocyte 
counts and viral load data, if available for HIV-infected patients, and outcome, including 
survival or death was obtained through record review. In addition, the surveillance officers 
were trained to test for HIV status, including in the provision of pre- and post-test HIV 
counselling, to patients for whom the HIV status was unknown at the time of admission. 
Surveillance officers recorded whether HIV status was known at admission and the outcome 
of HIV testing as part of the surveillance protocol (Appendix II). Where patients may have 
been too ill or too young to respond to questions, consent was obtained from relatives, to 
whom the questionnaire was administered, or permission was sought from local hospital 
authorities to conduct a record review. Incomplete data was marked as such on the case 
information form (CIF). Incomplete data and data gaps primarily occurred on record review 
after patients were lost to follow up, or where patients were obtunded or comatose and unable 
to respond. Where patients had been discharged or died before enrolment, permission was 
obtained from local hospital authorities to conduct a record review. Surveillance officers 
were regularly retrained at biannual meetings, to optimise clinical data collection.   
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Table 2. Elements evaluated in the Pitt bacteraemia score and corresponding values for 
analysis. These data should be routinely collected on all patients presenting with suspected 
sepsis at South African hospitals.  
Criteria for scoring are derived from Feldman et al (164). 
Clinical presentation Numerical Score Criteria for scoring 
Temperature 
Fever (oral temperature)  
- 2 (≤35°C or ≥40°C) 
- 1 (35.1–36.0°C or 39.0–39.9°C) 
- 0 (36.1–38.9°C) 
Patient’s temperature in ºC on the 
day the specimen was taken 
Blood pressure 
- 2 (≤90mmHg) 
- 0 (>91mmHg) 
- U (Unknown) 
Systolic blood pressure reading on 
the day the specimen was taken 
Mechanical 
ventilation 
- 2 (Yes) 
- 0 (No) 
- U (Unknown) 
Whether patient was on 
mechanical ventilation at the time 
the specimen was taken 
Cardiac arrest 
- 4 (Yes) 
- 0 (No) 
- U (Unknown) 
Whether patient suffered cardiac 
arrest on the day the specimen was 
taken 
Mental State 
- 0 (Alert) 
- 1 (Disorientated) 
- 2 (Stuporous) 
- 4 (Comatosed) 
- S (Sedated) 
- U (Unknown) 
Mental state of the patient on the 
day the specimen was taken 
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3.2. Microbiological characterisation 
Shigella and Salmonella isolates from normally sterile sites were subcultured by the 
diagnostic laboratory of origin onto Dorset egg transport media (NHLS, Johannesburg, South 
Africa) and transported to CED, NICD, Johannesburg. All isolates submitted to CED were 
characterised according to standard operating procedures (SOPs) of the NHLS. Briefly, 
biochemical characterisation was undertaken utilising either standard biochemical tube tests 
(NHLS, Johannesburg, South Africa) (2003 – 2009) or the Vitek ® 2 automated diagnostic 
platform (bioMérieux, Marcy l'Étoile, France). Antimicrobial susceptibility testing was 
conducted using Etests ® (bioMérieux) or the Vitek ® 2 (bioMérieux), according to SOPs of 
CED and the manufacturer’s instructions. Minimum inhibitory concentrations were recorded 
for the following antimicrobials: ampicillin, trimethoprim-sulphamethoxazole, tetracycline, 
nalidixic acid, ciprofloxacin, streptomycin, kanamycin or amikacin, ceftriaxone, ceftazidime, 
cefepime and imipenem (165). In addition, the double-disk method (MAST Diagnostics, 
Bootie, England) was used to identify extended spectrum β-lactamase (ESBL) production 
(165). Multidrug resistance (MDR) was defined as resistance to three or more antimicrobials 
or the combination of trimethoprim-sulphamethoxazole and two other antimicrobials. 
 
Molecular characterisation using multi-locus sequence typing (MLST) of Salmonella 
Typhimurium for the Salmonella meningitis study was undertaken, as described at the 
Salmonella MLST database (http://mlst.warwick.ac.uk/mlst/dbs/Senterica), including DNA 
sequencing the following housekeeping genes: aroC, dnaN, hemD, hisD, purE, sucA and 
thrA. DNA sequencing was performed using the BigDye Terminator Cycle Sequencing Kit 
(Applied Biosystems, Foster City, USA) and an Applied Biosystems 3500 Genetic Analyzer. 
DNA sequences were collated and analysed using the DNASTAR Lasergene (version 8.0) 
Software (DNASTAR, Inc., Madison, WI, USA), followed by analysis at the Salmonella 
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MLST database where allele numbers and a MLST sequence type (ST) were assigned. DNA 
sequencing was performed using the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, 
Foster City, USA) and an Applied Biosystems 3500 Genetic Analyzer. DNA sequences were collated 
and analyzed using the DNASTAR Lasergene (version 8.0) Software (DNASTAR, Inc., Madison, 
WI, USA), followed by analysis at the Salmonella MLST database where allele numbers and a MLST 
sequence type (ST) were assigned. 
 
Molecular characterisation of Salmonella Typhi isolates to define whether these were the H58 
haplotype was undertaken as follows: all isolates from known HIV-infected patients were 
amplified, using primers developed targeting the H58 gene, using a conventional polymerase 
chain reaction (PCR) (166). Each of these isolates was matched as closely as possible to one 
to two isolates from patients of the same age and from the same geographic location. A total 
of 185 isolates were tested. 
3.3. Statistical analysis 
Data were recorded in EpiInfo (Centers for Disease Control, Atlanta, GA, USA) and later 
into Access 2007 (Microsoft Corp, Redmond, WA, USA). Data were then extracted and 
imported into STATA version 11 or version 13 (StataCorp, College Station, TX, USA), for 
further statistical analysis. Incidence rates for papers I through III were calculated using 
population projections developed by  Actuarial Society of South Africa (ASSA) (167). 
Incidence measures were minimum incidence as there was no correction for 
underascertainment. Incidence rates for paper IV were calculated based on annual data 
published by Statistics South Africa, to make these data more comparable with data derived 
by NDoH (Appendix III) (www.statssa.gov.za). Basic analyses calculated odds ratios (ORs), 
95% confidence intervals (CIs) and P values for age range, sex, HIV status, PBS, other 
comorbidities, serotype for Shigella and nontyphoidal Salmonella serovars, multidrug 
KH Keddy 81-11384 PhD 
 
30 
 
resistance and ESBL production. For multivariate analysis, logistic regression was used to 
calculate adjusted odds ratios (AORs), including non-collinear variables, with an observed 
cut-off of P<0.1 for the univariate analysis. Patients with missing data were excluded from 
the analyses. The χ2 test was used to compare clinical and microbiological features where 
relevant. Additional statistical analysis including incidence rate ratios and Pearson’s 
correlation were used when applicable. Two-sided P values of <0.05 were considered 
significant throughout.  
 
The burden of disease was assessed for each of the disease manifestations investigated, that is 
invasive shigellosis (South Africa), Salmonella meningitis (South Africa), typhoid fever 
(South Africa) and iNTS (Gauteng Province only, due to large case numbers as well as the 
strength of the data in that province). For invasive shigellosis, Salmonella meningitis and 
typhoid fever; population data were used based on tables developed by the Actuarial Society 
of South Africa (ASSA) (167). For the iNTS study in Gauteng Province, data published by 
the National Department of Statistics were utilised for burden of disease calculations 
(www.statssa.gov.za), as these would act as a comparator for published data from National 
Department of Health (NDoH) for the numbers of adults accessing ART from 2004 to 2012 
(168). To calculate changing incidence rates of iNTS, viral load data were extracted from the 
CDW (as above) as a proxy for the numbers of patients accessing antiretroviral therapy 
(ART) in Gauteng Province and compared with published data from NDoH (168). 
3.4. Ethics 
Ethics approvals were obtained for the University of the Witwatersrand Human Research 
Ethics  Committee (HREC) (M110601, granted 24 June 2011). Prior ethics for the Enhanced 
Surveillance for cotrimoxazole [trimethoprim-sulphamethoxazole] resistance in South Africa 
project was obtained with the following clearance numbers: M02-10-42 and M081117, and 
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M060449 for general surveillance (Appendix IV). Additional institutional ethics were 
obtained where relevant, at each of the sentinel sites. All patients who were interviewed 
provided informed consent (and assent in the case of minors capable of understanding and 
providing assent), or in the case of minors or those unable to provide consent due to their 
mental status, consent was provided by the parent or guardian. For those patients for whom 
data were gathered from review of clinical records, consent could not be obtained, but this 
was acknowledged and accepted in the ethics clearance process. 
3.5. Funding 
This research has been supported by NICD/NHLS and the President’s Emergency Plan for 
AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under 
the terms of [5U2GPS001328] and, in part, for 2003-2006 by funds from the United States 
Agency for International Development’s Antimicrobial Resistance Initiative, transferred via a 
cooperative agreement [number U60/CCU022088] from the Centers for Disease Control and 
Prevention (CDC), Atlanta, Georgia. For 2007 - 2009, it was supported by the HHS Centers 
for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, 
STD, and TB Prevention (NCHHSTP), Global AIDS Program (GAP) Cooperative 
Agreement [U62/PSO022901]. 
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4. Results 
4.1. Invasive enteric infections 2003 – 2013, South Africa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*NTS, Nontyphoidal Salmonella  
†Paper I was published before 2013, when this study ended, thus the data presented in this paper do not reflect all the invasive Shigella cases 
from 2003 - 2013 
 
Figure 6. Flow chart indicating the breakdown of number of cases available for analysis and 
primary data for analysis for Papers I - V. 
38025 isolates received in CED (2003 – 2013) 
10111 invasive Shigella and Salmonella isolates 
429 Invasive Shigella cases 
(2003 – 2009)† 
9472 Invasive Salmonella cases (including Salmonella Typhi) 
855 Salmonella Typhi cases 8617 Invasive NTS* cases 
278 Salmonella meningitis cases 
Invasive Shigella cases 
(2003 – 2009) † 
Known age: 387 cases 
Known sex: 412 cases 
 
Enhanced surveillance data 
N=210 
Known HIV status: 120 cases 
Known outcome: 172 cases 
Salmonella Typhi cases 
(2003 – 2013) 
 Known age: 641 cases 
Known sex: 647 cases 
 
Enhanced surveillance data 
N=369 
Known HIV status: 150 cases 
Known outcome: 237 cases 
 
Invasive NTS* cases Gauteng 
(2003 – 2013) 
N=4886 
 Known age: 4661 cases 
Known sex: 4728 cases 
 
Enhanced surveillance data 
N=3106 
Known HIV status: 2158 cases 
Known outcome: 2481 cases 
 
Salmonella meningitis cases  
(2003 – 2013) 
Known age: 256 cases 
Known sex: 267 cases 
 
Enhanced surveillance data 
N=146 
Known HIV status: 92 cases 
Known outcome: 112 cases 
 
639 Invasive Shigella cases 
2003 - 2013 
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     Figure 7. Evolution of the conceptual framework based on data analysis. 
 
 
Cumulative outcomes: 
Risk factors – common and 
unique 
Accessibility of HAART 
Antenatal screening 
Interventions 
Recommendations: 
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 Surveillance  
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Between 2003 and 2013, a total of 38025 enteric isolates were received by CED for 
characterisation, of which 10111 (26.6%) were invasive. Of these, 1397 (13.8%) isolates 
were identified on audit of the CDW. Data extraction for this work is reflected in Figure 6. 
Full data for the period 2003 – 2013 were not included for patients with invasive shigellosis 
for the publication of Paper I: this analysis covered the period from 2003 – 2009 only, as this 
manuscript was published before the study ended. For the remaining analyses (Papers II to V) 
and illustrative purposes for incidence and age range in this monograph, data were extracted 
for the full period, to include invasive shigellosis from 2003 to 2013. 
 
Results of this work are published as five papers (Figure 7). Paper I analyses the association 
of HIV infection and invasive shigellosis in South Africa; Paper II describes the connection 
between HIV infection and meningitis in South Africa; Paper III examines the links between 
HIV infection and typhoid fever in South Africa and Papers IV and V analyse the association 
between HIV infection and iNTS in Gauteng Province, South Africa, the former specifically 
focussing on the correlation between increasing access to antiretroviral treatment (ART) and 
the latter primarily discussing clinical and microbiological aspects of iNTS and HIV. 
 
Annual incidence rates are reflected in Figure 8. While incidence rates for invasive 
shigellosis, typhoid fever and Salmonella meningitis were comparable, averaging from 0.05 
to 0.15 per 100,000 over the 11 year period, incidence rates for iNTS infection in Gauteng 
were much higher, peaking at 5.8 per 100,000 in 2004, thereafter decreasing to 2.2 per 
100,000 in 2013 (Figure 8). Higher incidence rates of typhoid fever were noted in 2005 and 
2006, in association with documented typhoid fever outbreaks (0.39 and 0.23 per 100,000 
respectively). 
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Figure 8. Comparative incidence rates per 100,000 population of invasive shigellosis, 
Salmonella meningitis, typhoid fever (South Africa) and invasive nontyphoidal Salmonella 
(iNTS) infection (Gauteng Province, South Africa) 2003 – 2013. 
Scales on the vertical axes reflecting incidence rates differ for iNTS incidence rates, due to 
higher overall numbers for iNTS. 
 
Of 6244 patients for whom sex was known, 3283 (52.6%) patients were male; where age was 
known, 1605/6131 (26.2%) were less than five years of age, 517 (8.4%) were aged between 5 
and 14 years; 439 (7.2%) were aged between 15 and 24 years; 3186 (52.0%) were aged 
between 25 and 54 years and 384 (6.3%) aged 55 years and older. For invasive shigellosis 
and iNTS, the majority of cases occurred in children < 5 years and adults aged from 25 to 54 
years, but for typhoid fever, the highest incidence rates were noted in the 5 to 14 year age 
band (Figure 9).  
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Invasive Shigella by age group and sex, South Africa, 2003 – 2009. Invasive nontyphoidal Salmonella meninigitis by age group and sex, South Africa, 2003 – 2013. 
 
 
Typhoid fever by age and sex, South Africa, 2003 – 2013. Invasive nontyphoidal Salmonella, Gauteng Province, South Africa, 2003 – 2013. 
Figure 9.  Age range and sex distribution in patients with invasive enteric infections in South Africa, 2003 – 2013 (data for invasive Shigella are 
for 2003 – 2009 only).
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4.2. Differences in HIV prevalence and mortality associated with age 
and sex in patients presenting with invasive enteric infections  
This work confirmed that HIV infection was a significant risk factor predisposing patients to 
invasive disease due to Shigella and nontyphoidal Salmonella (NTS), including Salmonella 
meningitis (Table 3). Prevalence rates of HIV infection in patients presenting with invasive 
enteric infection were higher in invasive shigellosis, Salmonella meningitis and iNTS in 
Gauteng (Papers I, II and V respectively). 
 
Data for typhoid fever were less conclusive: although HIV infection appeared to be a risk 
factor for typhoid fever in adult women, this could not be shown for adult men and neither 
was it observed in children. Additionally, in this series, excluding those patients with typhoid 
fever, between 95% and 100% of adults presenting with invasive enteric infection were HIV-
infected (Table 3). 
 
Comparing patients presenting with typhoid fever with those presenting with iNTS in 
Gauteng, at admission, 335/369 (90.8%) of patients with typhoid fever had unknown HIV 
status, compared with 1917/3106 (61.7%) of those presenting with iNTS. Post admission, 
219/369 (59.3%) of patients with typhoid fever still had unknown HIV status, compared with 
951/3106 (30.6%) of patients with iNTS (χ2=8.3; P=0.004). 
  
KH Keddy 81-11384 PhD 
 
38 
 
Table 3. Incidence of invasive enteric infections in known HIV- infected individuals† with known age, and in Gauteng for invasive nontyphoidal 
salmonellosis, compared with average national prevalence of HIV in South Africa, 2003 – 2013. 
 Total  HIV-infected  
 
% HIV-infected Odds ratio 95% Confidence interval P 
National data* (referent)       
 Children < 15 years 15493078 385955 2.5 - - - 
 Males ≥ 15 years 16161807 1986415 12.3 - - - 
 Females ≥ 15 years 17823516 2803527 15.7 - - - 
Study       
• Invasive shigellosis       
 Children < 15 years 61 23 37.7 23.7 (13.5 -  40.8) <0.001 
 Males ≥ 15 years 15 15 100 - - - 
 Females ≥ 15 years 44 42 95.5 112 (29.3 - 959.3) <0.001 
• Salmonella meningitis       
 Children < 15 years 46 24 52.2 42.7 (22.9 -  79.9) <0.001 
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 Males ≥ 15 years 23 23 100 - - - 
 Females ≥ 15 years 21 21 100 - - - 
• Typhoid fever       
 Children < 15 years 63 3 4.8 2.0 (0.4 – 6.0) 0.2 
 Males ≥ 15 years 44 7 15.9 1.4 (0.5 - 3.1) 0.5 
 Females ≥ 15 years 43 19 44.2 4.2 (2.2 - 8.1) <0.001 
• Invasive nontyphoidal 
salmonellosis 
(Gauteng) 
      
 Children < 15 years 504 322 63.9 69.3 (57.5 - 83.4) <0.001 
 Males ≥ 15 years 824 780 94.7 150 (108.2 - 215.2) <0.001 
 Females ≥ 15 years 816 779 95.5 94.8 (70.0 - 131.6) <0.001 
†Data reflect HIV status only for those patients for whom it was known at sentinel surveillance sites and not all cases identified. 
*Data averaged from ASSA calculations for population and HIV prevalence in South Africa, and in Gauteng for invasive nontyphoidal 
salmonellosis (167). 
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In Paper I, all adults (≥15 years) with invasive shigellosis were HIV-infected, but the burden 
of disease of invasive shigellosis in adults predominantly occurred in adult females (55/70; 
[78.6%] versus 25/48 [52.1%]; P=0.00]), but this predominance was not seen in the other 
studies (Papers II to V). Significantly, however, more adult women with typhoid fever were 
HIV-infected compared with adult men (19/44 [43.2%] versus 7/43 [16.3%]; P=0.009). In all 
the studies, adults aged ≥ 15 years were more likely to die than children aged < 15 years 
(Table 4). There were additionally differences in the incidence of HIV infection between 
females and males in association with Salmonella meningitis (35/41 [85.4%] versus 33/49 
[67.4%]; P=0.04) and a trend was observed for iNTS infection in Gauteng Province 
(916/1026 [89.3%] versus 962/1111 [86.6%]; P=0.06) (Paper V). 
 
Papers I, III and V confirmed that children aged < 15 years with invasive enteric infections 
were also less likely to be HIV–infected, compared with adults (Table 5). In paper II, all 
patients aged ≥ 15 years were HIV-infected: statistical analysis was therefore not possible on 
this cohort. Additionally, Paper IV confirmed that as access to ART increased over the period 
2003 – 2013, annual incidence rates of iNTS across all age groups decreased in Gauteng 
Province (R=-0.94; P<0.001). 
 
In association with these findings, paper IV showed that ART had had a significant impact in 
decreasing incidence rates of invasive nontyphoidal salmonellosis on adults aged 25 - 49 
years than on children aged < 5 years in Gauteng Province between 2003 and 2013 (R=-0.92; 
P<0.001 versus R=-0.50; P=0.14). Similarly, adults aged 25 – 49 years had a significantly 
greater negative correlation between decreasing incidence rates of Salmonella enterica 
serovar Typhimurium (Salmonella Typhimurium) compared with children aged < 5 years 
(R=-0.91; P<0.001 versus R=-0.67; P=0.04).  
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Table 4. Comparative risk factors for mortality due to invasive enteric infections between children aged < 15 years and adults ≥ 15 years. 
Study Cases Deaths Case 
fatality ratio 
Odds ratio 95% Confidence Interval (CI) P 
Children < 15 years (referent)       
• Invasive shigellosis 90 16 17.8 1 - - 
• Salmonella meningitis 57 19 33.3 1 - - 
• Typhoid fever 111 3 2.7 1 - - 
• Invasive nontyphoidal 
salmonellosis 
624 126 20.2 1 - - 
Adults ≥ 15 years       
• Invasive shigellosis 82 34 41.5 3.2 (1.6 – 6.6) 0.001 
• Salmonella meningitis 71 41 57.7 3.7 (1.7 – 8.1) 0.001 
• Typhoid fever 126 13 10.3 4.1 (1.1- 14.9) 0.03 
• Invasive nontyphoidal 
salmonellosis 
1854 632 34.1 2.0 (1.6 – 2.5) <0.001 
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Table 5. Comparative risk of invasive enteric infections associated with HIV infection between children aged < 15 years and adults. 
Study Children < 15 years 
N (%) 
Adults ≥ 15 years  
N (%) 
Odds ratio 95% Confidence Interval 
(CI) 
P 
 HIV-
uninfected 
HIV-
infected 
HIV-
uninfected 
HIV-
infected 
   
Invasive shigellosis 38 (62.3) 23 (37.7) 2 (3.4) 57 (96.6) 47.1 (10.3 - 419.7) <0.001 
Salmonella meningitis 22 (47.8) 24 (52.2) 0 (0.0) 45 (100.0) - - - 
Typhoid fever 60 (95.2) 3 (4.8) 61 (70.1) 26 (29.9) 8.4 (2.4 – 45.0) <0.001 
Invasive nontyphoidal 
salmonellosis 
182 (36.1) 322 (63.9) 81 (4.9) 1569 (95.1) 10.9 (8.1 – 14.8) <0.001 
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Reviewing male versus female case numbers for iNTS in Gauteng over the period, in adults, 
there was a significant difference in males versus females between the years 2003 - 2005 and 
2006 – 2013 (509/1,109 [45.9%] and  600/1,109 [54.1%] versus  1,139/2,122 [53.7%] and 
983/2,122 [46.3%] respectively; χ2=17.6, P<0.001) (Figure 10), which was not apparent in 
male and female children between the years 2003 - 2005 and 2006 – 2013 (207/371 [55.8%] 
and 164/371 [44.2%]) versus 545/948 [57.5%] and 403/948 [42.5%] respectively;  χ2=0.3, 
P=0.6) (Figure 11) (Table 6). The correlation however between adult males and females 
accessing ART and male and female children accessing ART between 2004 and 2013 was 
very good (Figure 12). Paper IV confirmed the rate ratio between adult men and women 
presenting with iNTS in 2003 and 2004 (rate ratio=0.73 and 0.89, respectively) reversed in 
2005 (rate ratio=1.07) and this trend was maintained until 2013 (rate ratio=1.44), in 
conjunction with consistently lower numbers of men accessing ART. 
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Table 6. Numbers and incidence per 100 000 population of male and female patients, adults, aged ≥ 15 years, and children, aged < 15 years, 
accessing ART and presenting with invasive nontyphoidal Salmonella (iNTS), in Gauteng Province, South Africa, between 2003 and 2013. 
Results for prevalence of ART usage and iNTS incidence are calculated from STATSSA population based numbers (Appendix III; 
www.statssa.gov.za).  
Year Patients accessing ART Patients presenting with iNTS Prevalence of ART usage per 100 000 Incidence of iNTS per 100 000 
 Adult Child Total Adult Child Total Adult Child Total Adult Child Total 
 Male Female Male Female  Male Female Male Female  Male Female Male Female  Male Female Male Female  
2003 - - - - - 137 195 54 46 432 - - - - - 3.6 5.1 4.1 3.4 4.2 
2004 2282 3921 607 604 7414 185 218 83 63 549 58.4 100.5 45.6 44.4 70.6 4.7 5.6 6.2 4.6 5.2 
2005 9924 18135 2437 2318 32814 187 187 70 55 499 247.6 454.8 179.9 168.0 305.8 4.7 4.7 5.2 4.0 4.7 
2006 23106 43521 4826 4925 76378 221 181 94 62 558 561.9 1066.5 350.5 353.0 696.6 5.4 4.4 6.8 4.4 5.1 
2007 35017 65670 6938 6842 114467 138 150 86 62 436 830.7 1573.7 495.2 484.2 1021.8 3.3 3.6 6.1 4.4 3.9 
2008 53428 99637 9047 9179 171291 179 139 92 57 467 1235.8 2334.1 635.5 641.8 1496.6 4.1 3.3 6.5 4.0 4.1 
2009 63445 120259 10153 10719 204576 157 108 66 50 381 1430.7 2753.7 702.6 740.7 1749.4 3.5 2.5 4.6 3.5 3.3 
2010 65343 128330 11201 11882 216756 138 115 69 56 378 1436.5 2872.1 764.2 811.9 1814.5 3.0 2.6 4.7 3.8 3.2 
2011 80277 161494 11443 12360 265574 97 105 47 42 291 1719.9 3531.2 771.2 836.5 2176.4 2.1 2.3 3.2 2.8 2.4 
2012 108134 217413 12814 14151 352512 111 95 48 45 299 2257.5 4643.0 853.6 949.6 2828.3 2.3 2.0 3.2 3.0 2.4 
2013 138174 272753 14011 15425 440363 98 90 43 29 260 2809.4 5683.5 925.6 1030.2 3459.7 2.0 1.9 2.8 1.9 2.0 
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Figure 10. Number of adults aged ≥ 15 years, male versus female, presenting with invasive 
nontyphoidal Salmonella (iNTS) in Gauteng Province, South Africa, 2003 – 2013. 
 
 
Figure 11. Number of children aged < 15 years, male versus female, presenting with invasive 
nontyphoidal Salmonella (iNTS) in Gauteng Province, South Africa, 2003 – 2013. 
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Figure 12. Comparison of incidence of number of patient presenting with invasive Salmonella (iNTS) per 100,000 population per year by sex 
and age group (adult versus child) and prevalence of number of patients accessing antiretroviral therapy (ART) per 100,000 population by age 
range, Gauteng Province, South Africa, 2004 – 2013.
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4.3. Invasive enteric infections in HIV-infected patients, markers of 
HIV, access to antiretroviral treatment and HIV as a risk factor for 
mortality 
In addition, Papers IV and V showed mortality decreased as access to ART increased. Most 
adult patients aged ≥15 years had CD4+ counts ≤50 cells: 18/24 (69.2%) for invasive 
shigellosis; 14/27 (51.9%) for Salmonella meningitis and 663/1308 (50.7%) for patients with 
iNTS infection in Gauteng province, but only 3/16 (18.8%) for adults with typhoid fever. A 
total of 8/80 (10.0%) patients with invasive shigellosis, 10/70 (14.3%) with Salmonella 
meningitis, 4/29 (13.8%) with typhoid fever and 291/1454 (20.0%) with iNTS infection in 
Gauteng were on antiretroviral treatment. A total of 1/76 (1.3%) infants with invasive 
shigellosis, 4/22 (18.2%) with Salmonella meningitis, 1/60 (1.7%) with typhoid fever and 
20/182 (11.0%) with iNTS infection in Gauteng children had a history of being HIV-exposed 
(born to HIV-infected mothers), but were HIV-uninfected. 
 
Papers I, II, III and V found a significantly increased risk of mortality among HIV-infected 
patients compared with HIV-uninfected individuals (Table 7). The highest CFR was in HIV-
infected patients with Salmonella meningitis (30/32 [93.8%]), and the lowest in those with 
typhoid fever (7/25 [28.0%]). 
 
In contrast to the findings described above, correlating the decreasing incidence rates of iNTS 
infection, and specifically Salmonella Typhimurium infection in Gauteng, compared with 
increasing access to ART (R=-0.94; P<0.001 and R=-0.93; P<0.001, respectively), there was 
an unexpected significant correlation between increasing incidence rates of invasive 
Salmonella Enteritidis and ART access across all age groups (R=0.95; P<0.001).
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Table 7. HIV infection as a risk factor for mortality due to invasive enteric pathogens. 
Study Cases Deaths Case 
fatality ratio 
Odds ratio 95% Confidence Interval (CI) P 
HIV-uninfected (referent)       
• Invasive shigellosis 40 5 12.5 1 - - 
• Salmonella meningitis 17 3 17.6 1 - - 
• Typhoid fever 120 4 3.3 1 - - 
• Invasive nontyphoidal 
salmonellosis 
260 41 15.9 1 - - 
HIV-infected       
• Invasive shigellosis 78 29 37.2 4.1 (1.5 – 11.8) 0.008 
• Salmonella meningitis 32 30 93.8 5.3 (1.4  - 20.0) 0.013 
• Typhoid fever 25 7 28.0 11.3 (3.0 - 42.4) <0.001 
• Invasive nontyphoidal 
salmonellosis 
1806 570 31.6 2.5 (1.7 – 3.5) <0.001 
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4.4. Invasive enteric infections and severity of illness as a risk factor 
for mortality. 
All clinical papers found severity of illness, (Pitt bacteraemia score [PBS] ≥ 4 for 
predominantly bacteraemic infections or Glasgow coma scale [GCS] ≤ 13 for Salmonella 
meningitis) was a risk factor for mortality on univariate analysis (Table 8). Critically, severity 
of illness remained a significant risk factor contributing to mortality in all the analyses on 
multivariate analysis, when adjusting for age, HIV status, other comorbid features, time 
period (2003 – 2005; 2006 – 2009; 2010-2013) analysed for typhoid fever and iNTS in 
Gauteng, or microbiological risk factors (specifically multidrug resistance or Salmonella 
serovar). 
 
In Paper II and III, on multivariate analysis, correcting for age, comorbidity and 
microbiological risk factors for mortality, severity of illness for Salmonella meningitis 
(GCS≤13) and for iNTS infection in Gauteng (PBS≥4),  remained significant (AOR, 18.7; 
95% CI, 3.0 – 118.5; P=0.002 and AOR, 6.3; 95% CI, 3.8 – 10.5; P<0.001, respectively), 
although for HIV infection, the adjusted analysis did not (AOR, 0.9; 95% CI 0.1 – 15.7; 
P=0.987 and AOR, 1.5; 95% CI 0.9 – 2.4; P=0.1, respectively). For typhoid fever (Paper III), 
however, correcting for other factors contributing to mortality, both HIV infection (AOR, 
10.8; 95% CI, 2.3 - 50.3; P=0.002) and severity of illness (PBS≥4) (AOR, 9.8; 95% CI, 1.6 - 
60.0; P=0.01) remained significant. Numbers in the invasive Shigella cohort (Paper I) were 
too small to analyse for severity of illness. 
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Table 8. Severity of illness as a risk factor for mortality due to invasive enteric pathogens. 
Study Cases Deaths Case fatality ratio Odds ratio 95% Confidence Interval (CI) P 
Severity of illness (referent) 
PBS<4; GCS>13 
      
• Invasive shigellosis‡ 124 29 23.3 1 - - 
• Salmonella meningitis† 5 33 15.2 1 - - 
• Typhoid fever‡ 177 11 6.2 1 - - 
• Invasive nontyphoidal 
salmonellosis‡ 
1731 460 26.6 1 - - 
Severity of illness 
PBS≥4; GCS≤13 
      
• Invasive shigellosis‡ 8 7 87.5 22.9 (2.7 – 194.2) 0.004 
• Salmonella meningitis† 10 8 80.0 21.6 (3.5 – 133.3) 0.01 
• Typhoid fever‡ 12 5 41.7 10.8 (2.9 – 39.5) <0.001 
• Invasive nontyphoidal 
salmonellosis‡ 
109 72 66.1 5.4 (3.6 – 8.1) <0.001 
‡Severity of illness defined as a Pitt bacteraemia score (PBS) ≥4. 
†Severity of illness defined as Glasgow coma scale (GCS) ≤13.  
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4.5. Microbiological risk factors associated with HIV infection, invasive 
enteric pathogens and mortality 
Microbiological risk factors for mortality were not consistent through this study. Paper I 
showed there were no differences between the occurrence of multidrug resistant (MDR) 
Shigella serotypes in HIV- infected and uninfected individuals (P=0.3) and HIV-infected 
patients were not more likely to die if infected with a MDR Shigella strain (P=0.2). 
Additionally, in Paper III, there were no differences between the occurrence of MDR 
Salmonella enterica serovar Typhi (Salmonella Typhi) between HIV-infected and HIV-
uninfected individuals (P=0.5) or the isolation of Salmonella Typhi H58 (P=0.3). HIV-
infected patients infected with MDR Salmonella Typhi were, however, more likely to die 
than HIV-uninfected patients (P=0.02). 
 
A trend was noted however among patients with Salmonella meningitis (Paper II): infection 
with Salmonella Typhimurium was a risk factor for mortality (Odds Ratio [OR], 3.0; 95% 
Confidence Interval [CI], 0.05 – 1.04; P=0.06). Additionally, Salmonella Typhimurium 
ST313 occurred more frequently in HIV-infected patients with Salmonella meningitis 
compared with other sequence types (P=0.03). In Paper V, in patients in Gauteng Province 
with iNTS infection, HIV-infected patients were more likely to be infected with Salmonella 
Typhimurium (χ2=120.1; P<0.001) or MDR Salmonella isolates (χ2=12.2; P<0.001). 
 
Additionally, as described in sections 4.3 and 4.4 above, Paper IV showed that iNTS 
infections and invasive Salmonella Typhimurium decreased as access to ART increased 
between 2003 and 2013, but incidence of Salmonella Enteritidis infection increased at a 
comparable rate to numbers of patients accessing ART. 
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5. Discussion 
While the relationship between HIV and invasive enteric diseases has long been described in 
Africa, a full understanding of clinical features, including the role of age, sex, severity of 
illness and microbiological features including organism serotype and antimicrobial resistance 
profiles in South African patients, has been lacking. This work was undertaken to fill these 
data gaps and to provide additional information that could assist in both the prevention of 
disease as well as the management of patients presenting with invasive enteric infections. 
This is the accumulation of eleven years of data from a unique national laboratory-based 
surveillance system, developed to optimise data collection in a resource-limited emerging 
economy, representing a wide range of sentinel sites around South Africa (Figure 13). 
 
 
Figure 13. View overlooking Edendale Hospital, an enhanced surveillance site. 
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5.1.  Clinical characteristics 
 
Whereas this work has highlighted the association between HIV-infected patients and 
invasive shigellosis in adults, as well as invasive nontyphoidal salmonellosis in causing 
bacteraemic infections and meningitis in adults, these associations were less clear in children. 
Rather, it appears that children under the age of 15 years, and particularly young children, 
may acquire disease not only in association with HIV infection, but also due to HIV 
exposure, due to maternal HIV infection, or in association with malnutrition (18;49). By 
contrast, the role of HIV in adult infections is undisputed (29;46;169-172).  
 
Novel findings have been highlighted in this work: Shigella is a common cause of diarrhoea 
and dysentery in children in developing countries (153). HIV-infected women have been 
shown to be at a greater risk of acquiring invasive shigellosis, possibly in association with 
their having the burden of child care of children with diarrhoea. Conversely, while sick 
children may place HIV-infected adults at risk, HIV-infected mothers may be placing their 
newborn infants at risk of Salmonella meningitis, possibly due to an inability to clear the 
pathogen from the gut and a failure to pass on maternal protective antibodies. Excessive 
numbers of young children, particularly those from disadvantaged backgrounds, presenting 
with invasive nontyphoidal salmonellosis, has been highlighted in the United States (173). 
This work confirmed both their vulnerability and that maternal HIV may impact even HIV-
uninfected infants (Figure 14). Interventions in known HIV-infected mothers have been 
shown to reduce neonatal mortality in Zambia (174): although, given the prevalence of 
trimethoprim sulfamethoxazole resistance in the South African nontyphoidal Salmonella 
isolates (>40%) would render this unfeasible, other antimicrobials may be appropriate in 
preventing mother-to-child transmission of disease. 
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Figure 14. The paediatric ward at Edendale Hospital, an enhanced surveillance sentinel site. 
 
This work could not resolve the risks of HIV-infected individuals for acquiring typhoid fever 
however, primarily due to data gaps regarding HIV status in patients with typhoid fever. 
While it appears that children and adult males were not at a greater risk, it suggested that 
adult females were: 43% of adult women with typhoid fever were HIV-infected compared 
with 16% of adult women in the general population. It is also well described in South Africa 
that women exhibit better healthcare seeking behaviour in relation to suspected HIV-related 
infections (157), and women who knew they were HIV-infected may have preferentially 
sought medical care at tertiary care facilities. As current HIV programmes in South Africa 
include antenatal testing of all pregnant women presenting to government antenatal clinics 
(175), most women of childbearing age who have had children are aware of their HIV status. 
This contradiction requires further clarification In addition, reviewing the proportion of 
patients who still had an unknown HIV status after admission for typhoid fever versus those 
patients admitted for iNTS in Gauteng Province, it appears that there is a clear and significant 
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bias towards testing patients with iNTS for HIV infection, compared with testing patients 
with typhoid fever.   
 
Of concern is the role that malnutrition plays in association with HIV infection in children. In 
a Zambian series, it was noted that HIV infection negatively affected the nutritional status of 
children with intestinal infections (44) and a similar result was noted here. The incidence of 
invasive nontyphoidal salmonellosis decreases significantly in association with  interventions 
including both HIV treatment programmes and nutritional interventions (146). 
5.2.  Mortality 
 
 
Figure 15. A school child walks past a graveyard with numerous fresh graves, Upington, 
Northern Cape. 
This thesis has highlighted again the powerful association between HIV as a risk factor for 
invasive enteric disease and additionally for mortality due to invasive enteric disease in South 
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Africa (Figure 15). Irrespective of whether invasive disease is due to Shigella, Salmonella 
Typhi or the non-typhoidal Salmonella, excessive mortality due to these pathogens is a cause 
for concern and odds ratios ranged from 2.5 for invasive nontyphoidal salmonellosis to 11.3 
for typhoid fever, comparing HIV-infected with HIV-uninfected individuals. Medrano et al 
have additionally described a higher frequency mortality in relation to HIV infection in 
patients in an intensive care facility (176). Adults were also between two and three times 
more likely to die than children less than 15 years of age, reflecting the excessive burden of 
HIV infection, particularly among adults aged 25 to 45 years of age (167). 
 
Additionally, severity of illness, including Glasgow coma scale (GCS) ≤13 in those patients 
presenting with Salmonella meningitis or Pitt bacteraemia score (PBS) ≥4, for those patients 
with bacteraemic infections, remains a critical aspect that must be considered in managing 
any patient with an invasive enteric infection, irrespective of whether they are HIV-infected 
or HIV-uninfected, due to excessive mortality associated with these patients. In fact, on 
multivariate analysis, HIV remained a significant risk factor for mortality only in those 
patients presenting with typhoid fever, compared with severity of illness. Interestingly, recent 
data suggest that irrespective of HIV or nutritional status, children presenting with certain 
cytokine profiles affecting neutrophil recruitment were more likely to die (177), highlighting 
additional host factors besides premorbid conditions. 
 
Mortality has nonetheless decreased significantly over the time period: this appears to be 
primarily due to the introduction of antiretroviral therapy (ART) in 2004 (10). This trend is 
particularly clear for iNTS disease and has been described by other authors in association 
with ART as an intervention for HIV-associated bacteraemias (147). This supports the critical 
role of ART in Africa, in controlling mortality due to HIV. 
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5.3.  Microbiological characteristics 
There was no significant difference between Shigella serotype and association with HIV 
infection or Shigella serotype and mortality: rather the predominant Shigella serotypes 
appeared to reflect those that are currently circulating in South Africa (58-64). Conversely, 
specific Salmonella serovars, and in particular Salmonella enterica serovar Typhimurium 
(Salmonella Typhimurium) ST313, was associated with HIV infection. Given the well-
described evolution of this latter pathogen in Africa, in association with HIV (115;116;148), 
the finding that this was significantly associated with HIV-infected patients with iNTS 
meningitis is unsurprising. Although sequence typing was not undertaken for those isolates 
that caused iNTS bacteraemia in Gauteng Province, these data strongly suggest that this 
sequence type is responsible for the majority of HIV-associated infections here. Salmonella 
Enteritidis appears to be associated primarily with HIV-uninfected individuals and has a 
lower case fatality ratio compared with Salmonella Typhimurium, but overall incidence rate 
is increasing. 
 
The incidence of invasive nontyphoidal salmonellosis is almost 40 times the incidence of 
invasive shigellosis: this may be due to intrinsic differences in the way these pathogens 
invade the gut epithelium. Specifically, Salmonella enterica  has adapted to invading 
macrophages, benefitting from the additionally protective phagolysosome (117), compared 
with Shigella, which survive in the cytosol (97) (see section 1). Additionally, however, 
Salmonella appear to have a unique ability to evolve to favour causing invasive disease: 
Salmonella Typhi diverged from other Salmonella serovars through the loss of primarily 
protein-encoding gene function as well as horizontal acquisition of several Salmonella 
pathogenicity islands (178). A similar evolutionary tale has been described for the host 
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adaptation of  Salmonella Typhimurium ST 313 (115;116;148) and new evidence suggests 
that a lineage of Salmonella Enteritidis is evolving to  cause infection in humans in Africa 
through the loss of selected areas of the genome as well (179). Whether this Salmonella 
Enteritidis clade has spread from central and East Africa to South Africa is unknown, thus 
whether it has a role in the increasing incidence of invasive Salmonella Enteritidis infection 
between 2003 and 2013 cannot yet be confirmed. 
5.4.  The role of antiretroviral treatment 
 
While the critical role of ART in decreasing incidence rates of iNTS is well-recognised and 
undeniable, data on the effectiveness of this intervention in South Africa are difficult to 
obtain. A partial publication by the National Department of Health (NDoH) referred to ART 
uptake in adults only (168). Otherwise, publications from South Africa (180) have relied on 
estimates of the Actuarial Society of South Africa (167). To ascertain whether iNTS 
incidence had decreased with the introduction of ART in 2004, this work utilised a previously 
evaluated methodology (181). Viral load tests in HIV-infected patients attending HIV clinics 
around Gauteng served as a proxy for the numbers of patients accessing ART. The highly 
correlated significant effect the ART programme has had on iNTS incidence rates, 
specifically invasive Salmonella Typhimurium, in adults aged between 25 and 49 years, is 
remarkable and testimony to the programme’s success in Gauteng Province and certainly 
confirms the programme is working under the more optimal conditions of South Africa’s 
wealthiest province (182). Whether the programme has been as successful in other provinces 
remains to be elucidated: these data have not been comprehensively analysed. 
 
The year 2006 appears to have been a watershed year for the ART programme, with both 
declining mortality in typhoid fever and iNTS and changing patterns in incidence rates. The 
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ratio of adult women to men presenting with iNTS in Gauteng, reversed between the early 
(2003 to 2005) and later (2006 to 2013) years of ART, greater numbers of women were 
observed in the former period. This may be ascribed to better health care utilisation in women 
(157). Both groups appeared to have a comparably good correlation between ART access and 
declining iNTS infection, however, indicating the success of ART as an intervention to 
decrease iNTS incidence rates.  
 
Where questions remain, these are around the contradictory results, indicating that invasive 
Salmonella Enteritidis has increased as Salmonella Typhimurium has decreased, despite the 
introduction of ART. It is possible that the human-adapted Salmonella Enteritidis strain 
described by Feasey et al (179), migrated into South Africa over the past few years, but 
additional complexities, such as food insecurity in a country that is becoming poorer, may 
also be contributory (183). Whatever the reasons, further work is mandatory in order to 
combat a new scourge and identify and implement appropriate interventions. 
 
Despite the introduction of a highly effective method to decrease opportunistic enteric 
infection in HIV, it is estimated that the disease still has a high cost of treatment averaging 
ZAR27,000 (USD1,800) per admission, primarily due to patients who were not on ART 
(158). In Kwazulu-Natal, high ART coverage (30 to 40% of all HIV-infected individuals 
receiving ART ) is associated with HIV-uninfected individuals being nearly 40% less likely 
to acquire HIV, than someone living in a community where ART coverage was low (<10% of 
all HIV-infected individuals receiving ART) (184). As this work specifically examined the 
decrease in iNTS in association with the number of people accessing ART in Gauteng, it is 
fair to conclude that ART is highly successful as an intervention for decreasing opportunistic 
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infection, but in those patients failing or unable to access ART programmes, the risk of 
succumbing to an opportunistic infection remains real. 
5.5  Public health relevance of these data 
This work has shown that HIV is intrinsically associated with invasive enteric infections, 
more specifically, invasive shigellosis and salmonellosis. More specifically it appears that 
invasive enteric pathogens, whether transmitted person-to-person, or acquired through 
exposure to contaminated food and water, have a considerable burden on morbidity and 
mortality in association with HIV. Figure 16 summarises the hypotheses and results of this 
thesis and highlights a number of achievable interventions. These would include optimizing 
antenatal screening protocols and ensuring that HIV-infected mothers obtain perinatal 
antiretrovirals, to ensure that the foetus is protected, and should additionally perinatal 
antimicrobials be considered, for those pregnant mothers who may be carrying Salmonella or 
Shigella in their gut. Additionally, this study has provided additional evidence that a 
treatment lag in HIV-infected adult males may be contributing to higher burdens of invasive 
Salmonella infections in the later years of the surveillance, supporting calls for additional 
HIV testing and improving access to HIV-related care among this population (157). New 
vaccines are under development for both Shigella (153) and nontyphoidal Salmonella (185), 
and once these become available, these may play a role in preventing person-to-person 
transmission, as well as protecting patients in the event of food or waterborne disease. 
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Theories: 
High risk of exposure to enteric 
pathogens → Enteric pathogens 
more likely to become systemic in 
immune suppressed individuals → 
Directed PH response will decrease 
morbidity/mortality 
Concepts: 
Shigella and Salmonella common enteric 
pathogens → RSA – one of the highest HIV 
rates in the world → HAART introduction 
2004→ Impact of HAART: additional 
resources/programmes to improve 
outcomes 
Research Question: 
Association of invasive 
enteric pathogens with HIV & 
other risk factors→  
Incidence Rates→ 
Associations/Outcomes/ 
Interventions/PH response 
Key Words: 
• HIV 
• Immune 
suppression 
• Nontyphoidal 
Salmonella  
• Salmonella 
Typhi 
• Shigella 
• Meningitis 
• HAART 
• Invasive 
disease 
Methods: 
Literature review →2⁰ data analysis →GERMS-SA CIF, CDW & 
laboratory data→ Clinical & microbiological data: 2003 – 2013 
Paper I: Systemic shigellosis in 
South Africa 
• Highly associated with 
HIV 
• Primarily older girls and 
women 
• Higher mortality in HIV 
Paper II: Salmonella meningitis 
in South Africa 
• Highly associated with 
HIV 
• Common cause of 
neonatal meningitis 
• HIV – predisposed to 
Salmonella 
Typhimurium ST313 
Paper IV/V: Systemic NTS, GP, RSA 
• Decrease case numbers (HIV & non-
HIV) d.t. HAART? 
• Lag time in roll out 
• HIV infection rates and CD4 counts 
(CDW). 
• Mortality associated with severity of 
illness, irrespective of HIV status 
Paper III: Typhoid fever & HIV 
• HIV +ve -higher risk of 
acquiring infection/ 
dying 
• HIV +ve no greater 
incidence of MDR 
pathogens /virulent 
isolates 
Cumulative outcomes: 
Risk factors – common & unique; Accessibility of ART; Antenatal screening & perinatal ARTs; Predominant 
pathogens/serotypes; Interventions / Recommendations: PH interventions – WASH, vaccines, vulnerable populations  
Surveillance – measure impact of HAART & other interventions; Health impact on HIV -ve 
Figure 16. Final conceptual framework integrating findings from thesis. 
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In addition, patient education on the value of accessing and remaining in these programmes 
are an important part of management. Further education programmes would include advising 
on the importance of “WaSH”  - water, sanitation and hygiene, which has previously been 
shown to be valuable in preventing infections in HIV-infected patients (186). Given that most 
new infections in South Africa appear to be in young women (187), WaSH would be a 
critical intervention, particular for decreasing invasive shigellosis. 
 
Although this thesis was primarily examining the association between invasive enteric 
infections and HIV, it has highlighted a number of vulnerable HIV-uninfected patients that 
would need to be managed as well. Specifically, childhood nutrition programmes, 
management of diseases including malignancy or organ failure and the elderly may all be 
included in interventions to decrease disease. 
 
Given the exceptionally strong association between increasing ART usage and decreasing 
iNTS incidence, particularly with reference to Salmonella Typhimurium, this study makes a 
strong argument for utilising data on new iNTS infections as an indicator of how successful 
the ART programme will continue to be. As iNTS infection is an acute disease, changing 
incidence rates will provide better indicator data than chronic infections such as tuberculosis 
(180) or cryptococcosis (188). 
 
Lastly, this work has described an evolving epidemic due to HIV in association with invasive 
enteric infections using laboratory-based surveillance data. This has provided powerful 
arguments for the extended value of the PEPFAR programme (161;162), which provided 
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additional value in developing the laboratory-based surveillance system for enteric 
pathogens. It is a testament to a farsighted and generous international public health 
programme and has argued strongly for a multifaceted approach in detailing and 
understanding challenges in public health, to provide viable answers and solutions to 
questions that such challenges may raise.  
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6. Limitations 
Despite this being one of the larger studies of its kind conducted, there were a number of 
limitations in this thesis. Inadequate data, particularly pertaining to HIV status was collected 
for the studies that included the smaller data sets (Paper I: systemic shigellosis; Paper II: 
Salmonella meningitis; Paper III: Typhoid fever), which prevented a complete analysis of the 
association of HIV status in susceptibility to and mortality due to these diseases. As this study 
was conducted at sentinel sites, it is also possible that there may have been a selection bias in 
these patients.  The sentinel sites in this study are all tertiary level hospitals, and most are 
academic centres as well: it is possible that patients who are aware that they are HIV-infected 
may preferentially refer themselves to such hospitals, or are already in HIV treatment 
programmes at these institutions. 
 
This may particularly be true in the case of the excessive numbers of adult women presenting 
with typhoid fever: women are preferentially tested for HIV infection, through the antenatal 
screening programmes in South Africa (175). Moreover, adult women, knowing their HIV 
status, may preferentially seek medical care at tertiary care facilities, thereby exhibiting 
Berkson’s bias (189). Low numbers of HIV results in this group of patients in particular make 
Berkson’s bias difficult to exclude. There is in addition the possibility that Berkson’s bias 
operated in reverse: once a clinician realised that a patient had typhoid fever, signs and 
symptoms would have been ascribed to this disease alone and the patient may not have been 
tested for HIV. This is borne out by the proportion of typhoid fever patients who still had 
unknown HIV status following admission, compared with those presenting with iNTS. 
 
Given the large numbers of patients included in the study on iNTS in Gauteng, which 
represented approximately half of the iNTS cases identified in South Africa during the study 
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period, and the consistency of the major findings, that HIV, disease severity and older age 
(adult patients) impact mortality, Berkson’s bias would have been less likely to have had a 
major impact or significantly alter the findings with regard to invasive nontyphoidal 
salmonellosis. Moreover, as the study patients were included based on a positive culture 
result from a normally sterile body site for invasive enteric infections, following which 
surveillance officers were requested to perform HIV testing in all patients for whom HIV 
status was unknown, this study did attempt to mediate the effect of Berkson’s bias through 
promoting testing of all patients who were enrolled. 
 
Other limitations include the fact that only a very small selection of the Salmonella 
Typhimurium received were sequence types, and only for those patients presenting with 
Salmonella meningitis. This work therefore cannot confirm that Salmonella Typhimurium 
ST313 had the same significant association with HIV in South Africa as it does in other 
African countries (116). Given the international data regarding the prevalence of this 
pathogens in association with HIV on the African continent and it’s prevalence in causing 
Salmonella meningitis in South African HIV-infected patients, it is reasonable to suppose that 
most of the Salmonella Typhimurium isolates we observed were Salmonella Typhimurium 
ST313. More detailed information on potential limitations can be found in each of the five 
papers. 
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7. Conclusions 
This study initially started as a project to examine the prevalence of trimethoprim-
sulphamethoxazole resistance in HIV-infected patients, before it was even thought that 
antiretroviral treatment (ART) programmes would be introduced into South Africa. When 
these were phased in from 2004, this provided an extraordinary opportunity to evaluate a 
large data set over a longitudinal period, both to describe the incidence of invasive enteric 
infections as well as to evaluate the response to ART. The work has highlighted that much 
needs yet to be done: besides the public health interventions suggested above, answers need 
to be sought for critical questions:  
• Invasive shigellosis appeared to decrease between 2003 and 2009, but updated 
information reviewed after the publication of Paper I suggests that it may be 
plateauing or on the rise: further information is required to understand these trends. 
• Better information is required as to why certain patients succumb to Salmonella 
meningitis, particularly to define if there is any associated infection such as 
cryptococcal disease or tuberculous meningitis; this may additionally need to be tied 
into potential predisposing host factors,  such as genetic predisposition to invasive 
Salmonella disease (190). 
• The association between HIV and typhoid fever remains problematic: low patient 
numbers meant that a conclusive result could not be obtained in this work and further 
surveillance is necessary to define whether HIV is in fact associated with higher 
disease rates. 
• The increase in the incidence of invasive Salmonella Enteritidis needs to be 
understood: whether this has been sustained since 2013, what the patient exposures 
are and what interventions can be done to counteract this increase. 
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• Access to ART as an intervention is problematic in certain groups, primarily adult 
men and potentially due to poorer health care utilisation: ongoing surveillance for 
iNTS will alert to defects in the ART programme and permit remedial action. 
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Abstract 
Background 
HIV-infected persons are at increased risk of invasive nontyphoidal Salmonella (iNTS) 
infections; antiretroviral therapy (ART) reduces this risk. We explored changing iNTS 
incidence at a population-based level associated with increasing ART availability in Gauteng, 
South Africa. 
Method 
Laboratory-based surveillance for iNTS was conducted in Gauteng between 2003 and 2013. 
Isolates were serotyped at the Centre for Enteric Diseases. The National Health Laboratory 
Service’s Central Data Warehouse (CDW) provided HIV viral load measurements data to 
estimate numbers of HIV-infected patients receiving ART. The association between iNTS 
incidence and ART use from 2004 to 2013 was described using Pearson’s correlation. 
Findings 
The annual incidence per 100,000 population of iNTS decreased from 5·0 to 2·2 from 2003 
to 2013 (p<0·001), while HIV viral load testing increased from 75·2 to 3,620·3 per 100,000 
from 2004 to 2013 (p<0·001). A strong correlation was observed between decreasing iNTS 
incidence and increasing ART use from 2004 to 2013 (r=-0·94, p<0·001).  Similarly, 
decreasing incidence of invasive Salmonella enterica serotype Typhimurium (Salmonella 
Typhimurium) infection correlated with increasing ART use (r=-0·94, p<0·001). Incidence of 
invasive Salmonella Enteritidis infection increased (r=0·95, p<0·001). Rates of iNTS in HIV-
infected men decreased less rapidly than in HIV-infected women; men accessed ART 
consistently less (p<0·001). 
Interpretation 
The incidence of iNTS infections including Salmonella Typhimurium decreased significantly 
in Gauteng associated with increased ART utilisation. Increasing incidence of invasive 
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Salmonella Enteritidis infections needs further elucidation. Population-based monitoring of 
iNTS incidence and viral load data may guide ART programmes, enhancing enrolment of 
HIV-infected men.  
Funding 
PEPFAR, USAID, CDC, NICD 
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Introduction 
Despite the introduction and rapid uptake of antiretroviral therapy (ART) in South Africa in 
2004,1 South Africa has among  the highest prevalence of HIV infection in the world.2 In 
2013, the estimated national seroprevalence of HIV infection in South Africa was 15% in 
adults aged 15 – 49 years,3 with an estimated 1000 new infections daily.4 High prevalence of 
HIV infection in South Africa places a tremendous burden on the health systems within the 
country, due in largely to opportunistic infections, including invasive non-typhoidal 
salmonellosis (iNTS). In parts of South Africa where ART coverage is high, declining HIV 
transmission rates and improvements in health-related quality of life have been noted.5 
Previous researchers have attempted to measure the impact of increased ART use among 
HIV-infected persons on the incidence of opportunistic infections in South Africa, with 
mixed results. Nunes et al showed increased ART use among HIV-infected persons was 
associated with declining morbidity and mortality in HIV-infected children due to invasive 
pneumococcal disease,6 but were unable to replicate these findings in HIV-infected adults.7 
Nanoo et al described a temporal decrease in the  incidence of microbiologically confirmed 
tuberculosis with increase antiretroviral use among HIV-infected individuals in South 
Africa,8 based on estimates of ART use, derived by the Actuarial Society of South Africa 
(ASSA).3  
The impact of increased ART use among HIV-infected persons on the incidence of iNTS in 
South Africa has not been defined, despite the well-described association of Salmonella 
enterica serotype Typhimurium (Salmonella Typhimurium) ST313 with iNTS among HIV-
infected persons in Africa.9-12 At the Queen Elizabeth Central Hospital in Malawi, following 
the introduction of ART, a 36% reduction in iNTS incidence in adults was described:13 
however,  it was unclear how much of the reduction in iNTS incidence in children in Malawi 
could  be ascribed to increased ART use since there were also improvements in nutrition 
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status and declines in prevalence of  malaria during this period.14 Researchers in other 
African countries have also recently described declines in iNTS incidence, but have not 
specifically related this decline to increased ART use.15,16 Concerns have also been raised that 
adult men may not be accessing ART programmes: Bor et al reported HIV-related mortality 
in a rural area of South Africa declined significantly more in women than men (p=0·05).17 
This study was undertaken to describe associations between iNTS incidence and ART use 
among HIV-infected persons in Gauteng Province, South Africa, a malaria-free province with 
an urbanised population with good health care access,4 low prevalence of malnutrition, and 
an HIV-seroprevalence of 11%.3 
Methods 
Invasive non-typhoidal Salmonella 
Between 2003 and 2013, the Centre for Enteric Diseases (CED) undertook active laboratory-
based surveillance for invasive non-typhoidal Salmonella (iNTS) at clinical diagnostic 
laboratories in Gauteng Province. Laboratories were requested to submit all Salmonella 
isolated from normally sterile sites to CED for further characterization, including serotyping. 
We defined iNTS infection as the isolation of non-typhoidal Salmonella from a normally 
sterile body site.  Data at the Central Data Warehouse (CDW) of the National Health 
Laboratory System (NHLS) were reviewed to confirm reporting of all iNTS infections: CDW 
is a repository for all public sector laboratory results in South Africa (representing over 80% 
of all facilities, >43 million people) which includes all microbiology and HIV-related 
laboratory tests conducted across public health laboratories. We recorded data on age and sex 
for all patients presenting with iNTS infection. All Salmonella isolates received were 
serotyped following CED standard operating procedures (Mast Group, Merseyside, UK; 
BioRad, Marnes-la-Coquette, France; Remel, Kent, UK; Statens Serum Institute, 
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Copenhagen, Denmark). Data were recorded in an Access 2007 database (Microsoft Corp, 
Redmond, WA, USA). 
Antiretroviral use among HIV-infected persons 
Since the availability of ART in 2004, routine management of HIV-infected persons in South 
Africa includes ART and measurement of HIV viral load at least annually; most patients on 
ART in South Africa have viral load testing performed at a NHLS laboratory. We therefore 
used CDW’s data on HIV viral load measurement tests to estimate the number of persons in 
Gauteng Province using ART from 2004 to 2013. Viral load data were de-duplicated by 
removing repeat viral load tests performed on the same patient in the same calendar year 
(supplementary table 1).  As a sensitivity analysis, we compared our estimate of the number 
of HIV-infected persons ≥15 years of age on ART to an unpublished report from the South 
African National Department of Health (NDoH).18   
Statistical Analysis 
To derive estimates of the incidence of iNTS and estimates of the incidence of the number of 
persons on ART, population denominators were derived from mid-year data estimates data 
published annually by the national Department of Statistics (www.statssa.gov.za). Incidence 
was also estimated for the following age groups: <5 years; 5 – 14 years; 15 – 24 years; 25 – 
49 years; and ≥50 years. 
A Poisson regression model was used to measure the change in incidence of iNTS infection 
from 2003 to 2013, and change in incidence of ART use from 2004 to 2013. We additionally 
determined the correlation between the incidence of iNTS and ART use from 2004 to 2013 
using Pearson’s correlation co-efficient. Analyses were performed using Stata version 13 
(StataCorp Limited, College Station, TX, USA). 
Results 
Invasive non-typhoidal Salmonella 
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From January 2003 – December 2013, we identified 4,886 cases of iNTS from Gauteng 
Province, South Africa. Sex was recorded for 4,728 (96·8%) patients: 2,478 (52·4%) were 
male. Ages were available for 4,661 (95·4%) patients, ranging from 0 days (newborn) to 93 
years, with a median of 32 years. The incidence of iNTS (cases per 100,000 population) per 
year increased from 5·0 in 2003 to 5·8 in 2004, after which there was a steady decrease to 2·2 
in 2013 (table 1).  The highest incidence of iNTS was in children <5 years of age; the lowest 
incidence was in children aged from 5 to 14 years (figure 1). 
 
Serotyping was completed on 4,459 (91·2%) of isolates: the most common serotypes were 
Salmonella enterica serovar Typhimurium (Salmonella Typhimurium) 2,469 (55·4%) and 
Salmonella Enteritidis, 1,156 (25·9%). 
 
The incidence of iNTS decreased from 2003 to 2013 (incidence rate ratio [irr]=0·91, 95% 
confidence interval [CI]=0·90 – 0·.92, p<0·001) (figure 1; supplementary table 2). By 
serotype, invasive Salmonella Typhimurium infections also decreased between 2003 and 
2013 (irr=0·79, 95% CI=0·78 – 0·81, p<0·001) (supplementary table 2). Invasive Salmonella 
Enteritidis infections, however increased over the same period (irr=1·14, 95% CI 1·12 – 
1·22, p<0·001) (supplementary table 2).  
ART use 
After removing repeat viral load tests on the same patient during the same calendar year, 
1,940,203 viral load tests were done in Gauteng between 2004 and 2013. Of these, 677,246 
(35·3 %) were done on male patients (19,511 had no gender stated) and 174,477 (9·0%) were 
done on children <15 years of age (supplementary table 1). Annually, the number of viral 
load tests increased as follows: 7,849 tests in 2004 (75·2 per 100,000 population); 2005: 
35,059 tests (326·7 per 100,000 population); 2006: 79,671 tests (726·6 per 100,000 
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population); 2007: 118,550 tests (1058·3 per 100,000 population); 2008: 176,950 tests 
(1,546·0 per 100,000 population); 2009: 209,445 tests (1,791·1 per 100,000 population); 
2010: 220,217 tests (1,843·4 per 100,000 population); 2011: 271,179 tests (2,222·4 per 
100,000 population); 2012: 360,432 tests (2,891·8 per 100,000 population); 2013: 460,806 
tests (3,620·3 per 100,000 population). 
Association between incidence of iNTS and incidence of ART use 
There was a correlation between increased use of ART and decreased incidence of iNTS 
infection per 100,000 population per year from 2004 to 2014· This correlation was observed 
in all age groups ≥5 years of age: (5 – 14 years, r=-0·69, p=0·03; 15 – 24 years, r=-0·84, 
p=0·002; 25 – 49 years, r=-0·92, p<0·001; ≥50 years, r=-0·70, p=0·02) (Figure 2a; 
supplementary table 3). Specifically analysing invasive disease due to Salmonella 
Typhimurium, there was a significant decrease in incidence which correlated with the 
increased use of ART from 2004 to 2013 (r=-0·93, p<0·001) (Figure 2b; supplementary table 
4). This correlation was not observed with invasive disease due to Salmonella Enteritidis, 
which increased significantly over the period (r=0·95, p<0·001) (Figure 2c; supplementary 
table 5). 
 
Comparing rates of iNTS infection against numbers of HIV-infected adult men versus those 
in HIV-infected adult women, between 2003 and 2004, fewer men presented with iNTS 
(2003, 29·9 versus 41·0, rate ratio=0·73; 2004, 38·7 versus 43·3 per 100,000, rate ratio=0·89 
respectively), but this was reversed from 2005 through 2013 (2005, 38·2 versus 35·5, rate 
ratio=1·07; 2006, 44·6 versus 33·1, rate ratio 1·36; 2007, 27·0 versus 25·3, rate ratio=1·06, 
2008, 35·3 versus 23·0, rate ratio=1·53; 2009, 31·3 versus 17·6, rate ratio=1·78; 2010, 27·7 
versus 18·4, rate ratio=1·78; 2011, 19·6 versus 16·5, rate ratio=1·51; 2012, 22·6 versus 14·8, 
rate ratio=1·53; 2013, 20·0 versus 13·7, rate ratio=1·44) (supplementary table 6). Regarding 
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access to antiretrovirals, adult men in Gauteng Province accessed ART consistently less than 
adult women, ranging from a rate ratio of 0·61 in 2004 to 0·67 in 2013 (2004 to 2013: 
p<0.001) (supplementary table 6). 
 
In the sensitivity analysis, there was a good correlation between number of HIV-infected 
persons ≥15 years of age on ART in the ASSA estimate and in our estimates (r=0·93, 
p<0·001) compared with the unpublished data from NDoH.18 
Discussion 
There is a high incidence of invasive salmonellosis in Africa, due to several important 
predisposing factors, including malaria, malnutrition and HIV infection11,19. In South Africa, 
the major contributing factor to invasive salmonellosis is HIV infection:20 the introduction of 
ART is thus critical to preventing iNTS infections. We examined the incidence of iNTS in 
Gauteng Province, which has a predominantly urbanised population, and documented a 
significant decrease in the incidence of iNTS cases in a period of increased ART utilisation 
which followed the introduction of ART in 2004. 
 
A decrease in iNTS incidence has been described in other countries in Africa where malaria 
is endemic.14-16 Malaria is an uncommon disease in South Africa, and Gauteng Province is 
malaria-free; therefore, we conclude that the decrease in iNTS incidence in South Africa is 
not due to malaria control efforts but due to the introduction of ART. In South Africa, almost 
all HIV-infected persons obtain ART through government HIV clinics. Our novel method for 
estimating the number of patients using ART takes advantage of the widely implemented 
HIV management protocol in South Africa that HIV-infected patients on ART should have 
viral load testing done at least annually to monitor their response to antiretrovirals.1 
Therefore, our study utilized data collected in a province where the population has good 
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access to healthcare, and included almost comprehensive HIV viral load data from HIV-
infected persons in this province. Other studies examining the association of tuberculosis and 
HIV in South Africa8 utilised the less complete ART use estimates from ASSA which are 
based on prospective statistical modelling.3 In our sensitivity analysis, we showed that our 
estimate of ART use, based on HIV viral load data, correlated well with the incomplete 
ASSA ART use estimates. However, because of the more robust data on viral load 
measurement tests used for our ART use estimates, we believe our estimate on ART is a 
better indication of the true number of patients accessing ART. 
 
Tanser et al showed a decline in HIV acquisition in HIV-discordant couples in South Africa, 
supporting the importance of the national antiretroviral programme in controlling HIV.21 We 
demonstrate the additional significant impact of ART on prevention of iNTS infection. 
Although we only examined data from a single province, ART use has been implemented in 
South Africa and these findings can likely be extrapolated to other provinces. 
We elected to separate children under five years from those aged 5 – 14 years for two 
reasons: firstly, as has previously been shown, children in the former age group are 
predisposed to a high mortality due to diarrheal diseases22 and may thus have different 
predisposing factors for iNTS. Secondly, there are differences in the HIV rates and clinical 
presentation between these two age groups; HIV-infected children living beyond five years 
were an unusual event prior to the introduction of perinatal ART and the ART roll-out.  
Our data showed a significant correlation between the declining incidence of Salmonella 
Typhimurium and increasing incidence of patients accessing ART, suggesting this serotype 
specifically may act as an indicator pathogen for the response to ART in South Africa. More 
specifically, this decrease was observed across individual age groups and most notably in 
patients aged 25 to 49 years, who bear the highest burden of HIV infection in South Africa.  
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An excessive burden of Salmonella Typhimurium, representing 85% of iNTS isolates, 
associated with multidrug resistance, has been described from other African studies and has 
been partly associated with HIV status.23 We have previously described the predominance of 
Salmonella Typhimurium ST313, associated with iNTS meningitis in HI- infected patients:12 
we suspect this particular pathogen, which emerged in Africa with the HIV epidemic,9 was 
equally responsible for  much of the invasive disease we identified here. 
The incidence of invasive disease due to Salmonella Enteritidis has increased in South Africa. 
This was observed across all age groups over the time period, despite the ART roll-out, and is 
not easily explainable. We suspect that this have been due in part to ill-defined associations 
between food safety and food security: the economic outlook of the country has decreased 
dramatically over the time period, with the gross domestic product (GDP) growth rate halving 
during the period (http://www.africaneconomicoutlook.org/en/statistics/table-2-real-gdp-
growth-rates-2003-2013/), although the population increased by approximately 50% 
(www.statssa.gov.za). In addition, new evidence suggests that some strains of Salmonella 
Enteritidis, similar to Salmonella Typhimurium ST313, may have become adapted in Africa 
to human-to-human transmission.24 Interestingly, Muthumbi et al conversely found 
Salmonella Enteritidis was replaced by Salmonella Typhimurium over the comparable time 
period.16 Salmonella Typhimurium appears primarily associated with  nosocomial 
transmission in South Africa.25 We suspect that as HIV transmission is controlled through 
various management programmes, the importance of other factors associated with iNTS in 
South Africa (Keddy et al, submitted), where malaria plays an insignificant role, will become 
more apparent: in the future, we may see disease trends comparable with those of 
industrialised countries in patients presenting with iNTS.11 
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It is concerning that adult men appeared to access ART at a slower rate than adult women, 
which may be translating into a greater risk of opportunistic iNTS. Previously we showed 
approximately 90% of iNTS cases in adults are HIV-associated (Keddy et al, submitted) and 
assumed that this would impact on the rates of HIV-infected men versus women presenting 
with iNTS from 2003 to 2013. In 2003 and 2004, when ART was introduced, iNTS incidence 
rates per 100,000 HIV-infected adult men were less than those in adult women, but this 
reversed in 2005, and has remained so through to 2013, as ART became more accessible to 
the Gauteng population. Excess HIV-associated mortality in adult men, in association with a 
delayed ART access has previously been described in South Africa:17 adult men may benefit 
from targeted interventions for HIV management programmes. 
 
This study has limitations. Firstly, although we attempted to comprehensively record Gauteng 
iNTS cases during the study period, some may have been were missed by our surveillance 
system. However, due the large numbers of patients with iNTS and extensive ART data from 
2004 to 2013, any potential effect of missed cases on our analyses would be minimal. 
Secondly, some HIV clinics possibly were not following HIV-management guidelines in 
obtaining HIV viral load estimates for patients on ART, resulting in our underestimating the 
number of HIV-infected persons on ART; we judge this to have limited effect on our findings 
since such underestimations are more likely to have occurred in more recent years, when 
greater numbers of HIV-infected persons were on ART.4 The most important limitation of 
this study is the ecological nature of the study design. However, the strong scientific evidence 
that ART prevents opportunist infections among HIV-infected persons clearly supports the 
plausibility of our finding that increased use of ART among HIV-infected persons is 
associated with a decreased incidence of iNTS infections, and our methodology was validated 
by our sensitivity analysis based on unpublished NDoH data. 
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In conclusion, we showed iNTS decreased dramatically in Gauteng Province, South Africa, 
particularly iNTS infections caused by Salmonella Typhimurium, during a period of 
increased ART utilisation. Continual monitoring of iNTS and Salmonella Typhimurium in 
particular, may act as an early alert to further successes or potential failures in the HIV 
treatment programme. We also noted a concerning increase in invasive Salmonella Enteritidis 
cases, for poorly understood reasons, needing further elucidation. Adult men may not be 
accessing ART programmes optimally and should be the focus of targeted interventions. Our 
data should significantly enhance current global efforts to define more accurate burdens of 
disease for invasive salmonellosis. It will also contribute to current understanding of how 
ART is accessed in countries with high burdens of HIV infection and allow better 
understanding how this access has decreased iNTS rates, independently of other 
interventions, such as malaria control, in Africa. 
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Table 1. Population and number (incidence per 100,000 population) of invasive non-
typhoidal Salmonella (iNTS) cases per year, Gauteng Province, South Africa, 2003 – 
2013.  
Year Population* Number of iNTS cases (iNTS incidence) 
2003 10,273,446 510 (5·0) 
2004 10,500,732 605 (5·8) 
2005 10,730,594 541 (5·0) 
2006 10,964,701 598 (5·5) 
2007 11,202,290 463 (4·1) 
2008 11,445,709 491 (4·3) 
2009 11,693,933 398 (3·4) 
2010 11,946,060 389 (3·3) 
2011 12,202,306 304 (2·5) 
2012 12,463,886 306 (2·5) 
2013 12,728,438 281 (2·2) 
*www.statssa.gov.za 
 
 
 
 
KH Keddy 81-11384 PhD 
 
144 
 
 
Figure 1. Incidence of invasive Salmonella per 100,000 population per year in Gauteng Province, South Africa, by age group, 2003 – 2013. (Test for trend: All ages, 
incidence rate ratio (IRR)=0.91, 95% CI=0.90 – 0.92, p<0.001; <5 years, IRR=0.95, 95% CI=0.93 – 0.96, p<0.001; 5 – 14 years, IRR=0.95, 95% CI=0.91 – 0.99, p=0.03; 15 
– 24 years, IRR=0.90, 95% CI=0.87 – 0.94, p<0.001; 25 – 49 years, IRR=0.89, 95% CI=0.88 – 0.90, p<0.001;  ≥50 years, IRR=0.96, 95% CI=0.94 – 0.99, p=0.007). 
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Figure 2a. Comparison of incidence of invasive Salmonella (iNTS) per 100,000 population per year by age range and incidence of number of patients accessing antiretroviral 
therapy (ART) per 100,000 population by age range, Gauteng Province, South Africa, 2004 – 2013.  
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Number of patients accessing ART               Number of invasive Salmonella Typhimurium cases  
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Figure 2b. Comparison of incidence of invasive Salmonella Typhimurium per 100,000 population per year by age range, and incidence of number of patients accessing 
antiretroviral therapy (ART) per 100,000 population per year by age range, Gauteng Province, South Africa, 2004 – 2013.  
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Figure 2c. Comparison of incidence of   invasive Salmonella Enteritidis per 100,000 population per year by age range, and incidence of number of patients accessing 
antiretroviral therapy (ART) per 100,000 population per year by age range, Gauteng Province, South Africa, 2004 – 2013. 
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Supplementary table 1. Population by age group (www.statssa.gov.za) per year, and number of persons (and incidence per 100,000 population) accessing antiretroviral 
therapy (ART) per year based on viral load testing extracted from the Central Data Warehouse,  Gauteng Province, South Africa, 2004 -2013. 
Year 
<5 years 5 - 14 years 15 – 24 years 25 – 49 years ≥50 years 
Population 
Population accessing 
ART 
(incidence) 
Population 
Population 
accessing ART 
(incidence) 
Population 
Population 
accessing ART 
(incidence) 
Population 
Population accessing 
ART 
(incidence) 
Population 
Population 
accessing ART 
(incidence) 
2004 980,499 606 (61.8) 1,709,956 649 (38.0) 1,853,453 392 (21.1) 4,552,587 5,396 (118.5) 1,404,237 474 (33.8) 
2005 977,015 2,669 (273.2) 1,757,046 2,234 (127.1) 1,868,051 1,758 (94.1) 4,653,273 24,231 (520.7) 1,475,210 2,488 (168.7) 
2006 971,544 5,413 (557.2) 1,800,450 4,587 (254.8) 1,887,926 4,065 (215.3) 4,752,778 56,850 (1,196.1) 1,552,003 6,340 (408.5) 
2007 961,731 7,229 (751.7) 1,852,191 6,823 (368.4) 1,911,049 5,691 (297.8) 4,843,434 85,640 (1,768.2) 1,633,885 10,187 (623.5) 
2008 960,768 8,892 (925.5) 1,892,937 9,580 (506.1) 1,940,398 8,235 (424.4) 4,932,900 128,965 (2,614.4) 1,718,706 16,768 (975.6) 
2009 971,248 9,302 (957.7) 1,920,887 11,789 (613.7) 1,972,974 8,845 (448.3) 5,023,297 154,129 (3,068.3) 1,805,526 21,670 (1,200.2) 
2010 991,519 9,835 (991.9) 1,937,694 13,550 (699.3) 2,006,540 8,677 (432.4) 5,116,721 161,513 (3,156.6) 1,893,586 24,610 (1,299.7) 
2011 1,013,711 8,628 (851.1) 1,947,754 15,505 (796.0) 2,039,462 11,439 (560.9) 5,217,804 199,613 (3,825.6) 1,983,575 32,539 (1,640.4) 
2012 1,020,369 9,040 (886.0 1,970,982 18,290 (928.0) 2,085,959 15,529 (744.5) 5,309,141 265,938 (5,009.1) 2,077,435 45,953 (2,212.0) 
2013 1,025,336 9,049 (882.5) 1,985,733 21,810 (1,098.3) 2,134,067 19,883 (931.7) 5,410,194 331,955 (96,135.7) 2,173,107 61,899 (2,848.4) 
KH Keddy 81-11384 PhD 
 
149 
 
Supplementary table 2. Test for trend of incidence of invasive nontyphoidal Salmonella (all 
serotypes, Salmonella Typhimurium, and Salmonella Enteritidis) per 100,000 population per 
year, by age group, in Gauteng Province, South Africa. 2003 – 2013. 
Characteristic IRR (95% CI) P 
All nontyphoidal Salmonella 0.91 (0.90 – 0.92) <0.001 
                                                   Age group    
<5 years 0.95 (0.93 – 0.96) <0.001 
5 - 14 years 0.95 (0.91 – 0.99) 0.03 
15 - 24 years 0.90 (0.87 – 0.94) <0.001 
25 - 49 years 0.89 (0.88 – 0.90) <0.001 
≥50 years 0.96 (0.94 – 0.99) 0.007 
    
Salmonella Typhimurium 0.79 (0.78 – 0.81) <0.001 
                                                   Age group    
<5 years 0.85 (0.82 – 0.87) <0.001 
5 - 14 years 0.85 (0.79 – 0.90) <0.001 
15 - 24 years 0.78 (0.72 – 0.82) <0.001 
25 - 49 years 0.78 (0.77 – 0.80) <0.001 
≥50 years 0.82 (0.78 – 0.85) <0.001 
    
Salmonella Enteritidis 1.14 (1.12 – 1.17) <0.001 
                                                   Age group    
<5 years 1.17 (1.12 – 1.22) <0.001 
5 - 14 years 1.22 (1.10 – 1.36) <0.001 
15 - 24 years 1.18 (1.08 – 1.30) 0.001 
25 - 49 years 1.11 (1.08 – 1.14) <0.001 
≥50 years 1.23 (1.16 – 1.30) <0.001 
IRR, incidence rate ratio; CI, confidence interval  
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Supplementary table 3. Incidence of invasive nontyphoidal Salmonella per 100,000 population per year by age group Gauteng Province, South Africa, 2004 – 2013. 
Year 
<5 years 5 - 14 years 15 – 24 years 25 – 49 years ≥50 years 
Number of invasive Salmonella 
cases  
(incidence) 
Number of invasive Salmonella 
cases  
(incidence) 
Number of invasive Salmonella 
cases  
(incidence) 
Number of invasive Salmonella 
cases  
(incidence) 
Number of invasive Salmonella 
cases  
(incidence) 
2004 133 (13.56) 17 (0.99) 34 (1.83) 333 (7.31) 41 (2.92) 
2005 119 (12.18) 16 (0.91) 30 (1.61) 298 (6.40) 51 (3.46) 
2006 145 (14.92) 22 (1.22) 26 (1.38) 339 (7.13) 45 (2.90) 
2007 132 (13.73) 23 (1.24) 24 (1.26) 225 (4.65) 42 (2.57) 
2008 129 (13.43) 20 (1.06) 14 (0.72) 252 (5.11) 59 (3.43) 
2009 103 (10.60) 15 (0.78) 28 (1.42) 192 (3.82) 49 (2.71) 
2010 104 (10.49) 22 (1.14) 20 (1.00) 174 (3.40) 61 (3.22) 
2011 77 (7.60) 13 (0.67) 11 (0.54) 146 (2.80) 49 (2.47) 
2012 79 (7.74) 14 (0.71) 13 (0.62) 145 (2.73) 49 (2.36) 
2013 65 (6.34) 9 (0.45) 15 (0.70) 128 (2.37) 45 (2.07) 
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Supplementary table 4. Incidence of invasive Salmonella Typhimurium per 100,000 population per year by age group, Gauteng Province, South Africa, 2004 – 2013. 
Year 
<5 years 5 - 14 years 15 – 24 years 25 – 49 years ≥50 years 
Number of invasive Salmonella 
Typhimurium cases 
(incidence) 
Number of invasive Salmonella 
Typhimurium cases 
(incidence) 
Number of invasive Salmonella 
Typhimurium cases 
(incidence) 
Number of invasive Salmonella 
Typhimurium cases 
(incidence) 
Number of invasive Salmonella 
Typhimurium cases 
(incidence) 
2004 84 (8.57) 11 (0.64) 22 (1.19) 248 (5.45) 30 (2.14) 
2005 54 (5.53) 8 (0.46) 19 (1.02) 220 (4.73) 41 (2.78) 
2006 84 (8.65) 16 (0.89) 18 (0.95) 263 (5.53) 29 (1.87) 
2007 71 (7.38) 10 (0.54) 7 (0.37) 122 (2.52) 23 (1.41) 
2008 53 (5.52) 12 (0.63) 9 (0.46) 145 (2.94) 31 (1.80) 
2009 27 (2.78) 5 (0.26) 15 (0.76) 73 (1.45) 17 (0.94) 
2010 32 (3.23) 10 (0.52) 6 (0.30) 68 (1.33) 21 (1.11) 
2011 10 (0.99) 1 (0.05) 1 (0.05) 31 (0.59) 9 (0.45) 
2012 12 (1.18) 3 (0.15) 1 (0.05) 19 (0.36) 6 (0.29) 
2013 7 (0.68) 1 (0.05) 0 (0.00) 15 (0.28) 5 (0.23) 
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Supplementary table 5. Incidence of invasive Salmonella Enteritidis per 100,000 population per year by age group, Gauteng Province, South Africa, 2004 – 2013.  
Year 
<5 years 5 - 14 years 15 – 24 years 25 – 49 years ≥50 years 
Number of invasive Salmonella 
Enteritidis cases 
(incidence) 
Number of invasive Salmonella 
Enteritidis cases 
(incidence) 
Number of invasive Salmonella 
Enteritidis cases 
(incidence) 
Number of invasive Salmonella 
Enteritidis cases 
(incidence) 
Number of invasive Salmonella 
Enteritidis cases 
(incidence) 
2004 4 (0.41) 4 (0.12) 4 (0.22) 43 (0.94) 3 (0.21) 
2005 9 (0.92) 9 (0.11) 2 (0.11) 26 (0.56) 3 (0.20) 
2006 13 (1.34) 13 (0.17) 1 (0.05) 33 (0.69) 7 (0.45) 
2007 19 (1.98) 19 (0.11) 5 (0.26) 42 (0.87) 6 (0.37) 
2008 22 (2.29) 22 (0.16) 1 (0.05) 53 (1.07) 15 (0.87) 
2009 24 (2.47) 24 (0.10) 3 (0.15) 60 (1.19) 17 (0.94) 
2010 27 (2.72) 27 (0.36) 7 (0.35) 69 (1.35) 21 (1.11) 
2011 32 (3.16) 32 (0.41) 6 (0.29) 80 (1.53) 28 (1.41) 
2012 38 (3.72) 38 (0.36) 8 (0.38) 96 (1.81) 32 (1.54) 
2013 40 (3.90) 40 (0.40) 12 (0.56) 83 (1.53) 32 (1.47) 
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Supplementary table 6. Comparison of number of HIV-infected adult men and women (> 15 years), invasive nontyphoidal salmonellosis incidence rates in adult men and 
women and adult men and women accessing antiretroviral therapy (ART) in Gauteng Province, South Africa, 2004 – 2013. 
Year Number of HIV-
infected patients* 
Number of invasive salmonellosis cases Male-to-
female 
rate 
ratio 
95% 
Confidence 
interval 
P Patients accessing ART Male-to-
female 
rate 
ratio 
95% 
Confidence 
interval 
P 
 Male Female Male iNTS/ 
100,000 
HIV-
infected 
Female iNTS/ 
100,000 
HIV-
infected 
Male ART/ 
1,000 
HIV-
infected 
Female ART/ 
1,000 
HIV-
infected 
2003 457,906 475,113 137 29.9 195 41.0 0.73 0.58 – 0.91 0.002 - - - - - - - 
2004 478,250 503,872 185 38.7 218 43.3 0.89 0.73 – 1.09 0.1 2,282 4.77 3,921 7.78 0.61 0.58 – 0.64 <0.001 
2005 490,114 526,817 187 38.1 187 35.5 1.07 0.87 – 1.32 0.2 9,924 20.24 18,135 34.42 0.59 0.57 – 0.60 <0.001 
2006 495,452 546,123 221 44.6 181 33.1 1.35 1.10 – 1.64 0.002 23,106 46.6 43,521 79.7 0.58 0.57 – 0.59 <0.001 
2007 511,784 592,102 138 27.0 150 25.3 1.06 0.83 – 1.35 0.2 35,017 68.4 65,670 110.9 0.62 0.61 – 0.62 <0.001 
2008 506,694 603,934 179 35.3 139 23.0 1.53 1.22 – 1.93 <0.001 53,428 105.4 99,637 165.0 0.64 0.63 – 0.64 <0.001 
2009 501,142 615,333 157 31.3 108 17.6 1.78 1.39 – 2.30 <0.001 63,445 126.6 120,259 195.4 0.65 0.64 – 0.65 <0.001 
2010 497,477 626,112 138 27.7 115 18.4 1.51 1.17 – 1.95 <0.001 65,343 131.3 128,330 205.0 0.64 0.63 – 0.65 <0.001 
2011 494,379 635,183 97 19.6 105 16.5 1.19 0.89 – 1.58 0.1 80,277 162.4 161,494 254.2 0.64 0.63 – 0.64 <0.001 
2012 491,862 642,927 111 22.6 95 14.8 1.53 1.15 – 2.03 0.001 108,134 219.8 217,413 338.1 0.65 0.64 – 0.65 <0.001 
2013 489,469 649,234 98 20.0 90 13.7 1.44 1.07 – 1.94 0.006 138,174 282.3 272,753 420.1 0.67 0.67 – 0.68 <0.001 
*Based on Actuarial Society of South Africa (ASSA) models3.  
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Abstract 
Background 
In Africa, HIV infection, malnutrition and malaria are important predisposing factors for 
invasive non-typhoidal Salmonella (iNTS) infections; factors associated with mortality 
among persons with iNTS infections are not well described.  
 
Methods 
Laboratory-based surveillance for iNTS, including sentinel site data (age, sex, HIV status, 
severity of illness and clinical outcome) was conducted in Gauteng, South Africa, from 2003 
to 2013. Isolates were serotyped and antimicrobial resistance profiles recorded. Clinical and 
microbiological differences between HIV-infected and uninfected patients were defined. Risk 
factors for mortality were calculated using univariate and multivariate analyses.  
 
Results 
Of 4,886 iNTS infections in Gauteng from 2003 to 2013, 3,106 (63.5%) were diagnosed at 
sentinel sites.  Among persons with iNTS infections, more HIV-infected persons were aged 
≥5 years (χ2=417.6; p<0.001) and more HIV-infected children were malnourished (χ2=5.8; 
P=0.02). On univariate analysis, mortality among persons with iNTS infections was 
associated with patients aged 25-49 years (odds ratio [OR]=2.2; 95% confidence interval 
[CI]=1.7 – 2.7; p<0.001) and ≥50 years (OR=3.0; 95% CI=2.2-4.1; p<0.001) compared with 
children aged <5 years, HIV-infected patients (OR=2.4; 95% CI=1.7-3.4; p<0.001) and  
severe illness (OR=5.4; 95% CI=3.6-8.1; p<0.001). On multivariate analysis, mortality was 
associated with patients ≥50 years (adjusted OR [AOR]=3.6, 95% CI=2.1 – 6.1, p<0.001) and 
severe illness (AOR=6.3; 95% CI=3.8 – 10.5; p<0.001). 
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Conclusions 
Mortality due to iNTS in Gauteng remains high primarily due to disease severity, irrespective 
of HIV status, indicating the need for interventions aimed at predisposing conditions, 
including HIV, other immune-suppressive conditions and malignancy. 
Funding 
PEPFAR, GAP (CDC) USA; NICD/NHLS (RSA)  
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Introduction 
Invasive non-typhoidal Salmonella (iNTS) infections are an important cause of morbidity and 
mortality in Africa. According to recent WHO Foodborne diseases Epidemiology Reference 
Group (FERG) estimates, there were approximately 600,000 iNTS infections, resulting in 
63,000 deaths, globally in 2010 (1); FERG estimated that 78% of iNTS infections occurred in 
the WHO Africa Region.  
 
Recent studies in several countries in Africa report high numbers of iNTS infections, 
commonly in association with malaria and HIV (2-6).  The multicentre Typhoid Fever 
Surveillance in Africa Programme (TSAP) study concluded that malaria is associated with a 
five times higher odds of iNTS disease (6). A number of studies have highlighted the high 
health burden of iNTS in children, frequently associated with malaria and malnutrition (3;5). 
Much work has also focussed on microbiological aspects of iNTS, including serotype and 
multidrug resistance (4;5), or iNTS disease burden (7). Several have called for development 
of nontyphoidal Salmonella vaccines (8). Although there have been reports of decreasing 
incidence of iNTS infections in some parts of Africa (7;9), mortality rates among persons 
with iNTS infections remain high (4;5;9) and factors associated with mortality among 
persons infected with iNTS are not well understood. A better understanding of disability and 
associated mortality of iNTS infections will inform decisions for control and prevention of 
iNTS infections (8). 
 
This study was undertaken to describe factors associated with mortality among persons 
infected with iNTS in Gauteng Province, South Africa, a largely industrialized urban 
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population in a malaria-free area, with an   HIV seroprevalence of 11% (10). We also 
explored the differences in clinical and microbiological features of iNTS infections in HIV-
uninfected versus HIV-infected individuals as these data may inform further management of 
iNTS disease. 
  
Methods 
Laboratory-based surveillance for invasive non-typhoidal Salmonella 
Between 2003 and 2013, the Centre for Enteric Diseases (CED) conducted active laboratory-
based surveillance for iNTS in all clinical diagnostic laboratories in Gauteng Province, South 
Africa. Invasive disease was defined as the isolation of non-typhoidal Salmonella from a 
normally sterile body site. Laboratory audits for additional iNTS cases in Gauteng Province 
were conducted by reviewing data in the Central Data Warehouse (CDW) of the National 
Health Laboratory System (NHLS), which stores results for all microbiology tests done by 
the NHLS (Keddy et al, in preparation). In selected sites, patients with iNTS infections had 
additional clinical information collected regarding HIV status, other co-morbid conditions 
(prematurity, protein-energy malnutrition [PEM], malignancy, autoimmune disorders, hepatic 
or renal disease), antimicrobial management, severity of illness (utilising the Pitt bacteraemia 
score [PBS] ≥4 to define severe infection (11)) and outcome (recovery versus death). If the 
patient with iNTS infection acquired iNTS infection after hospitalization for another reason, 
the iNTS infection was defined as a nosocomial-acquired infection. For HIV-infected 
patients, we additionally documented cotrimoxazole prophylaxis, antiretroviral therapy 
(ART) and CD4+ counts. Laboratories were requested to submit all Salmonella isolated from 
normally sterile sites to CED for serotyping and antimicrobial susceptibility testing. All 
Salmonella isolates received were serotyped following standard operating procedures (Mast 
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Group, Merseyside, UK; BioRad, Marnes-la-Coquette, France; Remel, Kent, UK; Statens 
Serum Institute, Copenhagen, Denmark). Minimum inhibitory concentrations (MICs) were 
determined for ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole (cotrimoxazole), 
tetracycline, ciprofloxacin, and ceftriaxone, using E-test strips, according to the 
manufacturer’s instructions (BioMérieux, Marcy-l’Étoile, France). Multidrug resistance 
(MDR) was defined as resistance to three or more of these antimicrobials (12). Extended 
spectrum β-lactamase (ESBL) production was measured using double disk testing, according 
to the manufacturer instructions (MAST Diagnostics, Bootie, England). Data were recorded 
in an Access 2007 database (Microsoft Corp, Redmond, WA, USA). 
 
Statistical Analysis 
Incidence was calculated using population denominators derived from data published 
annually by the National Department of Statistics (www.statssa.gov.za). To estimate risk 
factors for mortality due to iNTS, we calculated odds ratios (ORs), 95% confidence intervals 
(CIs) and p-values for age group, sex, HIV status, PBS, other comorbidities, serotype, 
multidrug resistance and ESBL production. For multivariate analysis, we used logistic 
regression to calculate adjusted odds ratios (AORs). Patients with missing data were excluded 
from the analyses. The χ2 test was used to compare clinical and microbiological features of 
HIV-uninfected with HIV-infected patients with iNTS. Two-sided P values of <0.05 were 
considered significant for all analyses. All statistical analyses were performed using STATA 
version 13 software. 
 
Results 
We recorded 4,886 laboratory-confirmed iNTS infections in Gauteng Province from January 
2003 – December 2013, of which 334 (6.8%) were identified using CDW data. Of 4,728 
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(96.8%) iNTS-infected patients for whom sex was recorded, 2,478 (52.4%) were male; 4,661 
(95.4%) patients had age recorded, ranging from 0 days (newborn) to 93 years, with a median 
of 32 years. The highest incidence of iNTS infection was in children aged <5 years, 
averaging 10.9 per 100,000 population per year during 2003-2013. The lowest incidence rate 
was in children aged 5 to 14 years (averaging 0.9 per 100,000 population per year).  
 
Serotyping was completed on 4,459 Salmonella isolates: the most common serotypes were 
Salmonella enterica serovar Typhimurium (Salmonella Typhimurium) (2,469 [55.4%]); 
Salmonella Enteritidis (1,156 [25.9%]); Salmonella Isangi (175 [3.9%]) and Salmonella 
Dublin (170 [3.8%]). Antimicrobial susceptibility testing results were available for 4,347 
(97.5%) isolates: 1,035 (23.8%) isolates were MDR, of which 381 (36.8%) were ESBL 
producers (Table 1). Salmonella Isangi (155/171 [90.6%]) had the highest prevalence of 
MDR among the most common serotypes, followed by Salmonella Typhimurium (808/2,240 
[36.1%]). MDR among Salmonella Enteritidis (20/1,149 (1.7%]) and Salmonella Dublin 
(1/165 [0.6%]) isolates was low. 
 
Sentinel site data 
Additional data from the sentinel sites were available for 3,106 (63.5%) iNTS-infected 
patients.  Outcome data were available for 2,481 (79.9%) iNTS-infected patients: 760 
(30.6%) patients died (Table 2). Mortality decreased over the time period (2003: 97/263 
[36.9%]; 2004: 114/301 [37.9%]; 2005: 107/302 [35.4%]; 2006: 113/311 [36.3%]; 2007: 
61/248 [24.6%]; 2008: 90/304 [29.6%]; 2009: 54/192 [28.1%]; 2010: 36/170 [21.2%]; 2011: 
39/147 [26.5%]; 2012: 23/123 [18.7%]; 2013: 26/120 [21.7%]). Comparing 2003-2005 with 
2006-2013, there was a significant decline in mortality among iNTS-infected persons (2003-
2005: 318/866 [36.7%] versus 2006-2013: 442/1,615 [27.3%]; χ2=18.6; p<0.001). 
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Of the patients with iNTS infections with available data, 1,900/2,158 (88.0 %) were HIV-
infected, 113/1,945 (5.8%) had a PBS≥4, 372/2,599 (14.3%) had a nosocomial-acquired 
iNTS infection, 458/2,218 (20.6%) presented with other co-morbidities and 127/638 (19.9%) 
children presented with PEM. Among 1,900 patients with iNTS infections who were HIV-
infected, CD4 counts were available for 1,308 (68.8%) patients: 663 patients (50.7%) had a 
CD4+ count between 0 and 50 cells per mm3, 217 (16.6%) had a CD4+ count between 51 and 
100, 239 (18.3%) had a CD4+ count between 101 and 200 and 93 (7.1%) had a CD4+count 
between 201 and 350 ; 293/1,457 (20.1%) patients had a previous or current history of ART 
use, including perinatal antiretrovirals (15 patients [5.1%]) and 426/1,354 (31.5%) patients 
were on cotrimoxazole. 
  
 HIV-infected versus HIV-uninfected patients 
Among persons infected with iNTS, comparing clinical features of HIV-uninfected with 
HIV-infected individuals, there were significant differences in age range: a significantly 
smaller proportion of HIV-infected patients were aged <5 years (HIV-infected: 256/1,896 
[13.5%] versus HIV-uninfected: 170/258 [65.9%]; χ2=417.6; p<0.001) (Table 2). HIV-
infected individuals were less likely to present with nosocomially acquired iNTS infection 
(HIV-infected: 235/1,881 [12.5%] versus HIV-uninfected: 59/253 [23.3%]; χ2=22.0; 
p<0.001) and were less likely to have other comorbid conditions (HIV-infected: 302/1,898 
[15.9%] versus HIV-uninfected: 96/258 [37.2%]; χ2=68.4; p<0.001) (Table 2). HIV-infected 
children presenting with iNTS were also more likely to be diagnosed with PEM (HIV-
infected: 81/322 [25.2%] versus HIV-uninfected: 29/182 [15.9%]; χ2=5.8; P=0.02). Among 
persons infected with iNTS, there was no significant difference, however, between severity of 
illness (PBS score≥4) between the two groups (HIV-infected: 79/1,415 [5.6%] versus HIV-
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uninfected: 9/204 [4.4%]; χ2= 0.5; P=0.5) (Table 2). HIV-infected patients were also more 
likely to present with invasive Salmonella Typhimurium compared with other serotypes 
(HIV-infected: 1,110/1,773 [62.6%] versus HIV-uninfected: 73/232 [31.5%]; χ2=118.0, 
p<0.001) or to present with MDR Salmonella isolates (HIV-infected: 491/1,753 [28.0%] 
versus HIV-uninfected: 38/224 [16.9%]; χ2=12.4; p<0.001) (Table 2). HIV-infected 
individuals were less likely to be infected with invasive Salmonella Enteritidis (HIV-infected: 
422/1,773 [23.8%] versus HIV-uninfected: 76/232 [32.8%]; χ2=8.8, p=0.003).  
 
Risk factors for mortality 
On univariate analysis, mortality among persons with iNTS infection was associated with 
patients aged 25 – 49 years compared with children aged< 5 years, (odds ratio [OR]=2.2; 
95% confidence interval [CI]=1.7 – 2.7; p<0.001) and with those ≥50 years of age compared 
with children aged< 5 years (OR=3.0; 95% CI=2.2-4.1; p<0.001), HIV-infected patients 
(OR=2.4; 95% CI=1.7-3.4; p<0.001) compared with HIV-uninfected patients,  more severe 
illness (PBS≥4) (OR=5.4; 95% CI=3.6-8.1; p<0.001) and infection with a MDR Salmonella 
(OR=1.9; 95% CI=1.5-2.3; p<0.001) (Table 3). On multivariate analysis, mortality among 
iNTS-infected persons was associated with patients ≥ 50 years of age (adjusted OR 
[AOR]=3.6, 95% CI=2.1 – 6.1, p<0.001), PBS ≥4 (AOR=6.3; 95% CI=3.8 – 10.5; p<0.001) 
and infection with MDR Salmonella (AOR=1.7, 95% CI=1.2-2.3, p=0.001), but not 
associated with being HIV-infected (AOR=1.4; 95% C=0.9-2.3; p=0.2) (Table 3). Analysing 
data on PEM in children, these patients were not significantly more likely to die compared 
with children who did not have PEM (OR=1.5; 95 % CI=1.0- 2.4; p=0.07) (Table 3). Among 
HIV-infected patients, those with CD4+ counts ≤350 were significantly more likely to die 
(OR=0.4; 95% CI=0.2-0.7; p=0.004), but a history of ART use did not significantly impact 
outcome (OR=0.8; 95% CI=0.6-1.1, p=0.1) 
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Discussion 
Invasive salmonellosis remains a challenge in Africa, due to a number of significant 
predisposing factors, including malaria, PEM in children and HIV infection (5;13;14). In 
South Africa, the major contributing factor to invasive salmonellosis is HIV infection (15). 
However, factors associated with mortality in patients infected with iNTS have not 
previously been well described. 
 
We examined disease burdens of iNTS in the predominantly urbanised population of Gauteng 
between 2003 and 2013, recording a significant decrease in the numbers of iNTS cases, 
following the roll out of ART in 2004 (Keddy et al, in preparation). Incidence for iNTS were 
highest among children <5 years and adults aged 25 to 49 years, highlighting the 
vulnerability of the former and the predominance of HIV-associated infections in the latter, 
supporting data from previous studies and systematic analyses (14;16). Similar to other 
African studies, the predominant serotypes were Salmonella Typhimurium and Salmonella 
Enteritidis, but we additionally identified increased numbers of Salmonella Isangi and 
Salmonella Dublin. Salmonella Enteritidis and Salmonella Dublin isolate were predominantly 
susceptible to the antimicrobials tested, but in common with other African studies, multidrug 
resistance was common in Salmonella Typhimurium (4;5) and Salmonella Isangi. Reports 
from Mali indicate that multidrug resistance occurred in >90% and 40% of Salmonella 
Typhimurium and Salmonella Enteritidis respectively (4), whereas reports from Kenya 
suggest that 36% to 77% of invasive Salmonella Typhimurium (5;17) and 30% of invasive 
Salmonella Enteritidis are multidrug resistant (17). In the Democratic Republic of the Congo 
multidrug resistance occurs in >80% of these two serotypes (18). Interestingly, multidrug 
resistance was low in Salmonella Dublin in Mali (4), similar to our findings. The 
KH Keddy 81-11384 PhD 
 
165 
 
predominance of Salmonella Typhimurium and Salmonella Enteritidis in Africa has 
highlighted these pathogens as primary serotypes for Salmonella vaccine development; the 
rapidly burgeoning multidrug resistance is making vaccine development an important 
imperative. 
 
 
There were additional differences between HIV-infected and HIV-uninfected individuals 
presenting with iNTS. Children aged less than five years with iNTS infections were less 
likely to be HIV infected (19). Additionally, more HIV-uninfected patients with iNTS had 
comorbidities including chronic organ failure or malignancy, highlighting non-communicable 
diseases as potential risk factor for iNTS infection. Although nosocomial-acquired iNTS 
infections appeared more frequently in HIV-uninfected patients, this study did not examine 
the role of HIV clinics in patients with iNTS. Data on long term care facilities were 
additionally not always forthcoming, thus this finding may not be truly reflective, as some 
HIV-infected patients in particular may have acquired iNTS while in these care facilities. 
Nosocomial salmonellosis is well described in South Africa, often affecting children (20;21) 
and nonetheless warrants careful monitoring. In contrast to invasive shigellosis (22), we did 
not see an excess of adult women presenting with iNTS: intrinsic characteristics of 
Salmonella, in HIV-infected patients in particular, appear to be at play in the context of 
invasive disease, beyond human behavioural factors. This has already been shown for 
Salmonella Typhimurium ST313 (23;24) and Salmonella Enteritidis (4;25). Further 
differences between HIV-infected versus uninfected individuals included Salmonella 
serotype: a significantly higher proportion of HIV-uninfected individuals presented with 
invasive Salmonella Enteritidis. This lesser association of Salmonella Enteritidis with HIV 
infection may partly explain why mortality due to this pathogen was significantly lower 
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compared with Salmonella Typhimurium. This contrasts with observations of  Tapia et al (4), 
who found a significantly higher case fatality of 27.8% associated with Salmonella Enteritidis 
compared with Salmonella Typhimurium in Mali, possibly in relation to a highly virulent 
clone in that country (4). HIV-infected patients in our series were more likely to be infected 
with multidrug resistant pathogens, which could be ascribed to their multiple exposures to 
antibiotics associated with management of other opportunistic infections (26). Severity of 
illness (PBS≥4) however was comparable between the two groups: irrespective of the 
primary illness, immune-suppressive conditions predispose patients to iNTS.   
 
Other researchers have highlighted the importance of underlying immunosuppressive disease, 
other than HIV, as the most important risk factor in adult patients for iNTS. Older patients, 
neonates and isolation of invasive serotypes were identified as risk factors for iNTS infection 
in HIV-uninfected patients (27). Malaria and malnutrition are important risk factors for iNTS 
in children (9). The excessive numbers of children in our series with iNTS who were HIV-
infected with PEM is concerning. HIV infection has been associated with undernourishment 
in children aged <5 years in South Africa (28;29), and clearly remains problematic. This may 
be  directly due to an HIV-associated effect in our study or due to other factors such as  
maternal illness or death (29). This may also be indicative of ongoing failures in nutritional 
programmes in primary health care (30). Feasey et al have clearly shown that iNTS rates 
decrease when childhood nutrition programmes are introduced (9) and greater emphasis may 
be needed on such programmes in South Africa .  
  
We elected to analyse data for children aged less than five years separately from those aged 5 
to 14 years to correspond to incidence data that have been calculated for iNTS and ART 
programmes in Gauteng Province, South Africa (Keddy et al, in preparation). Firstly,  the 
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younger group is predisposed to higher mortality due to foodborne diseases, including 
salmonellosis (1).  Secondly, differences in the HIV rates and presentation with iNTS 
between these two age groups may impact analyses: HIV-infected children surviving beyond 
five years of age was an unusual observation before the ART roll-out. Many of these patients 
in our series had associated malignancies or other predisposing immune-suppressive 
conditions as opposed to HIV infection. We have shown iNTS incidence rates in children 
aged <5 years correlates poorly with ART treatment programmes (Keddy et al, in 
preparation). Additional factors, such as HIV exposure in HIV-uninfected infants born to 
HIV-infected mothers, may also be at play, as has been postulated for neonatal Salmonella 
meningitis (23). 
 
We characterised risk factors for mortality due to iNTS, with a view to highlighting 
interventions to decrease mortality rates. Mortality among persons with infected with iNTS 
has decreased significantly after the introduction of ART, in other African studies (31) and 
we have observed a similar trend, but clinical risk factors needed clarification. HIV infection 
on univariate analysis, and the severely ill (PBS≥4), adults ≥25 years, and those with MDR 
isolates were associated with excessive mortality on multivariate analysis. Older age and 
disease severity were the most significant predictors of a poor outcome: excessive mortality 
occurs in patients with severely immunosuppressive conditions predisposing to iNTS, besides 
HIV infection, including, malignancy, organ failure and prematurity (27). In HIV-infected 
persons, we found mortality was associated with patients with a low CD4+ count, who also 
bore the greatest burden of illness, but not with ART use, supporting global initiatives for 
earlier initiation of ART (32). 
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This study had some limitations. Firstly, although we attempted to comprehensively identify 
the majority of the Gauteng iNTS cases during the study period, it is possible that some were 
not identified by our surveillance system, which focussed primarily on patients presenting to 
public hospitals. Indications and use of blood cultures are unlikely to have changed over the 
period, however, and the majority of cases (~60%) were identified in sentinel surveillance 
hospitals. This study also did not look at the impact of delayed or inappropriate antimicrobial 
therapy on mortality. Complete clinical information was not available for all cases at sentinel 
hospitals, but total case numbers were large. This should minimize the effect on the statistical 
analysis. Similarly, missing isolates constituted <10% of those characterised; we believe that 
the serotyping and drug resistance data are representative and it is unlikely those iNTS cases 
that were identified on audit would have significantly altered our findings.  
 
In conclusion, we showed although mortality due to iNTS in South Africa has decreased it 
remains high irrespective of the patients’ HIV status. We additionally noted a concerning 
increase in invasive cases of Salmonella Enteritidis across all age groups (Keddy et al, in 
preparation), for reasons that are not well understood and needing further elucidation. These 
observations, in combination with the prevalence of multidrug resistant Salmonella 
Typhimurium in Africa, support the need for the development of vaccines for these serotypes. 
As ART becomes even more readily available in South Africa, with more patients and older 
patients  accessing antiretroviral programmes, we may see a change in disease patterns of 
iNTS to more closely resemble those of the developed world  (14).  
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Research in context 
Evidence before this study 
We conducted a literature review of the PubMed database for the terms “invasive Salmonella” AND 
“HIV” AND “malaria” AND “malnutrition”, refining the searches further by adding “Africa” , 
“antiretroviral treatment”, “antiretroviral therapy” or “ART” and “mortality” to the search terms. We 
identified a number of studies that discussed risk factors for invasive salmonellosis and decreasing 
mortality rates, but there was a dearth of publications examining risk factors for mortality. There were 
also no studies directly comparing HIV-infected with HIV-uninfected individuals in Africa. 
Added value of this study 
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We believe that this may be the largest study published from Africa and the only one representing a 
national surveillance system, examining invasive nontyphoidal salmonellosis. This study has 
highlighted that although incidence and mortality rates due to invasive salmonellosis may be 
decreasing, patients have remained at high risk for mortality, particularly in association with severity 
of illness, irrespective of HIV status, and in the elderly. Mortality remains at ~20%.  We have 
moreover highlighted an added vulnerability in HIV-infected children, who are more likely to be 
malnourished and confirmed that it is a disease of severe immunosuppression in HIV, with more than 
50% of patients having a CD4+ count of 0 to 50 cells per mm3.  
Implications of all the available evidence 
In context with other studies from Africa, we have shown that a number of interventions may benefit 
the management of invasive salmonellosis, including childhood nutrition programmes, HIV 
management and treatment of other comorbidities that may place HIV-uninfected patients at risk of 
invasive Salmonella infection. We have uniquely highlighted risk factors for mortality, which will 
assist in individual case management and provided hard data to support early intuition of antiretroviral 
treatment. We have confirmed that multidrug resistance in invasive Salmonella is an urgent and 
continent-wide challenge. In addition, the predominant invasive serotypes we identified included 
Salmonella Enteritidis and Salmonella Typhimurium, which supports current initiatives for vaccine 
development programmes against these two pathogens. 
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Table 1. Serotyping and antimicrobial resistance for invasive non-typhoidal Salmonella isolates (N=4,347), Gauteng Province, South Africa, 2003 – 2013.  
Serotype and 
number of isolates 
tested (n) 
Ampicillin 
n (%) 
Chloramphenicol 
n (%) 
Trimethoprim- 
Sulphamethoxozole 
n (%) 
Tetracycline 
n (%) 
Ciprofloxacin 
Intermediate 
n (%) 
Ciprofloxacin 
Resistant 
n (%) 
Ceftriaxone 
n (%) 
ESBL* 
producers 
n (%) 
Multidrug 
resistance 
n (%) 
Typhimurium 
  
  
        
  
  
  
(n=2,420) 1,651 (68.2) 933 (38.6) 1,491 (61.6) 1,048 (43.3) 784 (32.4) 63 (2.6) 232 (9.5) 324 (13.4) 808 (33.3) 
Enteritidis 
  
  
  
  
    
  
  
  
(n=1,149) 43 (3.7) 30 (2.6) 38 (3.3) 127 (11.1) 344 (29.9) 5 (0.4) 6 (0.5) 7 (0.6) 20 (1.7) 
Isangi 
  
  
  
  
    
  
  
  
(n=171) 165 (96.5) 163 (95.3) 157 (91.8) 167 (97.7) 130 (76.0) 7 (4.1) 113 (66.1) 104 (60.8) 155 (90.6) 
Dublin 
  
  
  
  
    
  
  
  
(n=166) 5 (3.0) 5 (3.0) 6 (3.6) 5 (3.0) 3 (1.8) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 
Other 
  
  
  
  
    
  
  
  
(n=441) 138 (31.3) 91 (20.6) 144 (32.7) 167 (37.9) 56 (12.7) 11 (2.5) 41 (9.3) 39 (8.8) 51 (11.6) 
Total                   
(n=4,347) 2,002 (46.1) 1,222 (28.1) 1,836 (42.2) 1,514 (34.8) 1,137 (26.2) 86 (1.9) 392 (9.0) 474 (10.9) 1,035 (23.8) 
*ESBL, Extended Spectrum β-lactamase  
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Table 2. Clinical and microbiological features associated with HIV infection and invasive 
salmonellosis in Gauteng province South Africa, 2003 – 2013.  
 HIV uninfected 
n (%) 
HIV infected 
n (%) 
χ
2
 p 
Sex     
Male 147 (13.2) 963 (86.8) 4.1 0.04 
Female 107 (10.4) 920 (89.6) - - 
     
Age     
<5 years 170 (39.9) 256 (60.1) 417.6 <0.001 
5 - 14 years 12 (15.4) 66 (84.6) - - 
15 - 24 years 10 (8.6) 106 (91.4) - - 
25 - 49 years 40 (3.0) 1,281 (97.0) - - 
≥50 years 26 (12.2) 187 (87.8) - - 
     
Pitt bacteraemia (severity of illness) score   
< 4 195 (12.7) 1,336 (87.3) 0.5 0.5 
≥ 4 9 (10.2) 79 (89.8) - - 
     
Nosocomial infection    
No 194 (10.5) 1,646 (89.5) 22.0 <0.001 
Yes 59 (20.1) 235 (79.9) - - 
     
Comorbidity     
No 162 (9.2) 1,596 (90.8) 68.4 <0.001 
Yes 96 (24.1) 302 (75.9) - - 
     
Protein energy malnutrition (children<15 years) 
No 153 (38.8) 241 (61.2) 5.8 0.02 
Yes 29 (26.4) 81 (73.6) - - 
     
Salmonella serotype     
Typhimurium 73 (6.2) 1,110 (93.8) 118.0 <0.001 
Enteritidis 76 (15.3) 422 (84.7) - - 
Isangi 18 (28.1) 46 (71.9) - - 
Dublin 10 (13.2) 66 (86.8) - - 
Other serotypes 55 (29.9) 129 (70.1) - - 
     
Salmonella multidrug resistance   
No 186 (12.9) 1,262 (87.1) 12.4 <0.001 
Yes 38 (7.2) 491 (92.8) - - 
     
Salmonella ESBL† production   
No 201 (11.6) 1,529 (88.4) 1.1 0.3 
Yes 23 (9.3) 224 (90.7) - - 
†Extended spectrum β-lactamase 
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Table 3. Risk factors for mortality among persons with invasive non-typhoidal Salmonella with known outcome (N=2481) in Gauteng Province, South Africa, 
2003 – 2013.  
 Cases  
 
Deaths 
 
CFR* 
 
Univariate analysis Multivariate analysis** 
Characteristic n  n  (%) OR (95% CI) p AOR (95% CI) p 
Sex          
Male 1,301 416 32.0 - - -    
Female 1,156 334 28.9 0.9 0.7 – 1.0 0.1 0.8 0.6 – 1.1 0.2 
          
Age          
<5 years 534 101 18.9 - - - - - - 
5 - 14 years 90 25 27.8 1.6 1.0 – 2.7 0.05 1.4 0.6 – 3.3 0.4 
15 - 24 years 132 34 25.8 1.5 1.0 – 2.3 0.08 1.8 0.9 – 3.5 0.1 
25 - 49 years 1,435 480 33.5 2.2 1.7 – 2.7 <0.001 2.7 1.7 – 4.2 <0.001 
≥50 years 287 118 41.1 3.0 2.2 – 4.1 <0.001 3.6  2.1 – 6.1 <0.001 
          
HIV status          
Uninfected 255 41 16.1 - - - - - - 
Infected 1,811 572 31.6 2.4 1.7 – 3.4 <0.001 1.4 0.9 – 2.3  0.2 
          
Pitt bacteraemia (severity of illness) score       
< 4 1,731 460 26.6 - - - - - - 
≥ 4 109 72 66.1 5.4 3.6 – 8.1 <0.001 6.3 3.8 – 10.5 <0.001 
          
Nosocomial infection         
No 2,099 639 30.4 - - -    
Yes 355 112 31.5 1.1 0.8 – 1.3 0.7    
          
Other co-morbid conditions        
No 1,679 506 30.1 - - -    
Yes 437 132 30.2 1.0 0.8 – 1.3 1.0    
          
Protein energy malnutrition (children<14 years)**       
No 503 96 19.1       
Yes 124 33 26.6       
KH Keddy 81-11384 PhD 
 
179 
 
          
CD4+ count (HIV-infected patients only)‡       
CD4+ ≤350 1,193 365 30.6       
CD4+ >350 94 15 16.0       
          
Antiretroviral treatment (HIV-infected patients only)‡       
No 1,106 389 27.7       
Yes 287 66 23.0       
          
Salmonella serotype         
Typhimurium 1,329 465 35.0 - - - - - - 
Enteritidis 567 137 24.2 0.5 0.5 – 0.7 <0.001 0.8 0.6 – 1.1 0.2 
Isangi 84 30 35.7 1.0 0.7 – 1.6 0.9 1.7 0.8 – 3.9 0.2 
Dublin 94 20 21.3 0.5 0.3 – 0.8 0.008 0.5 0.2 – 1.1 0.07 
Other serotypes 224 108 26.5 0.8 0.6 – 1.1 0.2 1.3 0.8 – 2.1 0.3 
          
Salmonella multidrug resistance        
No 1,678 464 27.7 - - - - - - 
Yes 588 245 41.7 1.9 1.5 – 2.3 <0.001 1.7 1.2 – 2.3 0.001 
          
Salmonella ESBL† production**        
No 1,995 606 30.4 - - -    
Yes 271 103 38.0 1.4 1.1 – 1.8 0.01    
CI, confidence interval; OR, odds ratio; AOR, adjusted odds ratio 
*Case fatality rate 
**Excluded from multivariate analysis: multivariate analysis includes all age groups; multidrug resistance includes ESBL producing isolates 
‡Excluded from multivariate analysis: multivariate analysis includes both HIV-infected and HIV-uninfected patients 
†Extended spectrum β-lactamase 
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Appendix II: Case Investigation Form: GERMS-SA  
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Appendix III: Population data used for incidence rate analysis for Paper IV from Statistics South Africa 
(www.statssa.gov.za) 
Age 2003 2004 2005 2006 2007 2008 
(years) Male Female Male Female Male Female Male Female Male Female Male Female 
0 - 4 484385 494252 488029 492470 489522 487493 490222 481321 487864 473867 488628 472140 
5 - 14 817509 843329 841892 868064 865000 892046 886478 913972 913134 939057 934874 958063 
15 - 24 911834 937732 917758 935696 929508 938542 944686 943240 959879 951171 978377 962021 
25 - 49 2290029 2155126 2345814 2206773 2397531 2255741 2448049 2304729 2496769 2346665 2545039 2387861 
≥50 614325 724924 646684 757553 681745 793465 719425 832578 758760 875124 799862 918844 
Total 5118082 5155364 5240176 5260556 5363306 5367288 5488861 5475840 5616406 5585884 5746780 5698929 
Grand total 10273446 10500732 10730594 10964701 11202290 11445709 
 
Age 2009 2010 2011 2012 2013 
(years) Male Female Male Female Male Female Male Female Male Female 
0 - 4 493955 477293 503307 488212 513229 500483 515322 505047 517229 508108 
5 - 14 951069 969818 962400 975294 970593 977161 985785 985197 996499 989234 
15 - 24 998644 974330 1019368 987172 1034659 1004802 1055748 1030211 1077401 1056666 
25 - 49 2593653 2429644 2643534 2473187 2702271 2515533 2757022 2552119 2815959 2594235 
≥50 842313 963213 885778 1007808 930625 1052949 977165 1100270 1024965 1148142 
Total 5879634 5814299 6014387 5931673 6151378 6050928 6291042 6172844 6432053 6296385 
Grand total 11693933 11946060 12202306 12463886 12728438 
KH Keddy 81-11384 PhD 
 
185 
 
Appendix IV: Ethics clearance certificates 
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Appendix V: Turn-it-in Report 
 
